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Abstract
Riboswitches are cis-acting gene regulatory RNAs, which function without in-
volvement of proteins. They have been implicated as drug targets and are at-
tractive systems for the study of RNA-ligand binding and RNA folding.
The purine riboswitch was used as a model system for RNA-ligand docking.
Published binding data was successfully reproduced in silico and compounds pre-
dicted to bind the riboswitch in a virtual screening were tested experimentally.
Structural data confirming the predicted binding mode for several cases was ob-
tained. The problems encountered were not specific to RNA-ligand docking but
known from the far more explored field of protein-ligand docking.
The SAM-I riboswitch was also subjected to virtual ligand screening. This recep-
tor is a system of greater complexity than the purine riboswitch and consequently
posed a harder challenge to the docking protocol. After initial validation of the
docking setup based on previously published data, a set of compounds selected
from the in-house database of commercially available compounds was screened.
One compound identified in silico was confirmed to bind experimentally.
The k-turn motif found in the SAM-I riboswitch was investigated with respect
to its folding. The k-turn motif was found to be foldable in context of the SAM-
I riboswitch as well as in isolation as was expected. Furthermore, mutations
disrupting key interactions within the k-turn motif were found to be prohibitive
of k-turn folding in isolation as well as in context of the riboswitch, leading
to a loss of ligand binding. Interestingly, two sequences were identified which
fold in context of the riboswitch but do not fold in isolation. This confirms the
contribution of tertiary interactions to k-turn folding. This conclusion was backed
up with structural data.
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Chapter 1
Introduction
1.1 Antibiotics and the need for new drugs
1.1.1 Antibiotics
The term antibiotic was coined in the late 40s of the last century by Selman A.
Waksman (Waksman, 1947): ”An antibiotic is a chemical substance, produced
by micro-organisms, which has the capacity to inhibit the growth of or even to
destroy bacteria and other micro-organisms.”
Nowadays antibiotics can include synthetic or semi synthetic substances, thus not
requiring to come from a microbial source. Antibiotics have been known since the
1920s, and have had a huge impact on human health (Demain, 2009). Before an-
tibiotics were available, infectious diseases were the most common cause of death.
Millions of patients succumbed to infections like pneumonia and gastroenteritis,
which today are usually easily treatable by antibiotics.
One of the first major antibiotics, penicillin, is a substance isolated from Peni-
cillium fungi (Fleming, 1929) and it is still used to treat bacterial infections in
humans. Later, synthetic penicillin and slightly modified molecules were intro-
duced as well as other naturally occurring substances and derivatives of those
(Demain, 2009). Most antibiotics used today are derivatives of naturally oc-
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curring substances and act on a number of targets essential in bacterial growth.
Penicillin is an inhibitor of cell wall synthesis, but other antibiotic targets include
DNA gyrase (Pommier et al., 2010), DNA dependent RNA polymerase (McClure
and Cech, 1978) and the ribosome (Hermann, 2005).
1.1.2 The need for new drugs
The effort to discover new drugs, in particular antibiotics, needs to continue for
two reasons:
1. There are still diseases for which there is no satisfactory treatment available
2. Resistance against many commonly used antibiotics has emerged and thus
they become ineffective as a consequence.
Due to the extensive use of antimicrobial drugs, resistant strains of pathogens
have emerged and pose a serious health threat (Hawkey, 2008). In hospital envi-
ronments, a large fraction of the occurring infections are caused by bacteria such
as Staphylococcus aureus, that are resistant to several or virtually all available
antibiotics for treatment (Hawkey, 2008). For a long time vancomycin served as
the last resort in these cases, since no resistant strains were known and this drug
was used as a means of last resort. However, in 1987 vancomycin resistant strains
of bacteria were found (Lu¨tticken and Kunstmann, 1988) and more cases of van-
comycin resistant pathogens have emerged since. For a number of pathogens,
e.g. Mycobacterium tuberculosis, and S. aureus, strains have been isolated from
patients that are resistant to all antibiotics used for treatment. Therefore, the
efforts in drug discovery for infectious diseases must continue to ensure effective
treatment options in the future. One possible path is to explore new targets and
make these available for structure-based drug discovery. These new targets could
be found in functional RNA entities.
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1.2 RNA
1.2.1 RNA in biology and disease
The field of RNA research has advanced hugely over the last years. RNA molecu-
les have been shown to be essential factors in almost every process in living cells.
The new functions discovered for RNA molecules have changed the perception
of RNA. Instead of being viewed as a class of static messenger molecules, RNA
is now widely regarded as an essential and active contributor in processes like
transcriptional (Bayne and Allshire, 2005; Winkler et al., 2003) and translational
(Jovanovic and Hengartner, 2006; Sen and Blau, 2006) regulation, protein func-
tion (Manche et al., 1992; Sledz et al., 2003) and catalysis (Fedor and Williamson,
2005; Lilley, 2011; Thomas and Hergenrother, 2008).
Additionally, the importance of RNA factors in many disease states has been
demonstrated. The portfolio of diseases with significant involvement of RNA
factors includes cancer (Muniyappa et al., 2009), diabetes mellitus (Guay et al.,
2011) and infectious diseases (Huang et al., 2011). A special class of RNA-
related diseases is represented by the RNA viruses which pose a serious threat to
human health. RNA viruses store their genomic information in RNA form rather
than in DNA form. Among the most prominent of these viruses are the human
immunodeficiency virus (HIV; Frankel and Young 1998), the hepatitis C virus
(HCV; Ashfaq et al. 2011) and the influenza viruses.
1.2.2 RNA as a drug target
RNA molecules offer a valid target for intervention into disease related biological
processes. Many functions of RNA in biologically-important processes do not
involve proteins and even in RNA-protein complexes, the RNA component is
often essential (Fedor and Williamson, 2005; Autexier and Lue, 2006).
In the last decades all RNA-targeting drugs used in the clinic have been antibi-
13
otics targeting the large or the small subunit of the ribosome (Lin et al., 1997;
Bozdogan and Appelbaum, 2004; Hermann, 2005).
In the ribosome, the RNA constitutes the active component for both proof-
reading (Yoshizawa et al., 1999) and peptide bond formation (Rodnina et al.,
2007). Consequently, it is unsurprising that many antibiotics targeting the ri-
bosome do so by acting on the ribosomal RNA of both the small and the large
ribosomal subunit (Hermann, 2005). For example, tetracycline binds to the small
ribosomal subunit preventing the binding of aminoacyl-tRNA (Brodersen et al.,
2000). Macrolide antibiotics have been shown to bind the large ribosomal sub-
unit, more specifically the ribosomal RNA (Hansen et al., 2002).
The antimicrobials targeting RNA prove, that manipulation of cellular processes
via RNA targets is possible. Most of the antimicrobials of this category are
not molecules with ”drug-like” properties (Lipinski, 2001). Aminoglycosides and
macrolide antibiotics violate the ”rule of five” in several ways. They exceed a
molecular weight of 500, contain more than 5 hydrogen bond donors and 10
hydrogen bond donors. Additionally, these antibiotics contain a large amount
of stereo centers, which in conjunction with their size makes them difficult to
synthesize. However, it has been shown that RNA molecules can bind virtually
any type of ligand, implying that drug-like molecules can be used in principle to
interfere with RNA function. RNAs specifically binding very diverse chemicals
have been generated by in vitro selection (Tuerk and Gold, 1990). Among these
ligands for which RNA aptamers have been generated (Fig. 1.1) are theophylline
(Jenison et al., 1994), citrulline, valine, tryptophan and flavin mononucleotide
(FMN; Wilson and Szostak 1999).
In the light of these data it is unsurprising that in addition to the ribosome
several other functional RNA species have been proposed as drug targets. Some
prominent examples are tRNAs (Walter et al., 2002), the HIV-1 TAR element
(human immunodeficiency virus 1 trans-activation response element; Frankel and
Young 1998; Lind et al. 2002), riboswitches (Blount et al., 2007; Lee et al., 2009;
14
Figure 1.1: Ligands for which artificial aptamers have been isolated. These lig-
ands include nucleobase analogs like theophylline as well as amino acids and
FMN.
Mulhbacher et al., 2010) and ribozymes (Mulhbacher et al., 2010).
1.2.3 Computational drug discovery and RNA
Drug discovery is the process of identifying, validating and testing a chemical
compound as a therapeutic agent against a selected medical condition. The iden-
tification of candidate chemicals binding a molecular target is one of the first
hurdles that must be overcome. In modern drug discovery in silico methods
such as virtual ligand screening have become a very important tool for the dis-
covery of novel ligands for any given target (Ripphausen et al., 2010). Among
the various virtual screening techniques, molecular docking has proven to be a
powerful method for the discovery of novel ligands from a large set of candidate
compounds. Molecular docking predicts the three-dimensional binding mode of
given compounds to the receptor binding site and estimates the binding affinity.
A plethora of docking algorithms and scoring functions have been developed in
the past and excellent reviews on the topic are available (Klebe, 2006; McInnes,
2007; Yuriev et al., 2011). While docking has been extensively applied to pro-
teins, only few docking studies for RNA targets have been published and studies
including experimental validation of obtained docking results are even rarer (Fulle
and Gohlke, 2010). However, with the available structural data that emerged in
15
recent years, structure based computational methods are being applied to RNA
targets (Franceschi and Duffy, 2006; Schwalbe et al., 2007; Serganov, 2010). The
studies of RNA-ligand docking recently reported follow one of two approaches:
1. adaptation of methods and scoring functions originally developed for pro-
tein ligand docking (Lind et al., 2002; Detering and Varani, 2004; Kang
et al., 2004; Moitessier et al., 2006; Park et al., 2008; Lang et al., 2009; Li
et al., 2010)
2. development of entirely new methods tailored to RNA targets (Morley and
Afshar, 2004; Barbault et al., 2006; Pfeffer and Gohlke, 2007; Guilbert and
James, 2008)
Most of these studies attempt to reproduce available binding data, with varying
degrees of success. For the newly developed methods reproduction of previ-
ously described binding modes and enrichment of known ligands from a large
set of compounds with unknown binding properties have been reported. Morley
and Afshar 2004 use RiboDock with an empirical scoring function. This scoring
function is then validated by reproduction of binding modes of reported NMR
solution structures and enrichment factor experiments for the TAR RNA. Bar-
bault et al. 2006 use a neural neural network to develop a scoring function to use
with the Autodock software. The developed method is then used to reproduce
binding data for RNA-aminoglycoside complexes. Pfeffer and Gohlke 2007 fol-
low a slightly different approach by deriving a knowledge based scoring function
based on several hundred nucleic acid - small molecule and nucleic acid - pro-
tein complex crystal structures. The resulting scoring function is then validated
by prediction of binding affinities for 15 RNA-ligand complexes. Guilbert and
James 2008 developed a software called ’MORDOR’ and validated it against a
set of 57 RNA-ligand complex structures from the PDB. For 74 % of this set the
binding mode could be predicted with an RMSD of < 2.5 A˚. Using the ’MOR-
DOR’ software (Pinto et al., 2008) reported the discovery of novel ligands for
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human telomerase RNA with affinities between 180 µM and 1.5 mM . However
no structural confirmation of the reported binding modes was obtained. For the
application of docking software from the protein field the situation is similar.
Most well-known docking programs from the protein field have been applied to
RNA targets: DOCK (Detering and Varani, 2004; Kang et al., 2004; Moitessier
et al., 2006), DOCK6 (Lang et al., 2009) AutoDock (Detering and Varani, 2004),
FlexX (Park et al., 2008), Glide (Li et al., 2010) and Gold (Li et al., 2010). These
studies with the exception of Park et al. 2008 only report predictions for ligands
already known to bind. Park et al. 2008 additionally report novel compounds for
the selected target, a pseudoknot inducing ribosomal frame shifting. The binding
of these compounds is determined by a frame shifting assay and no KD values
are reported. Many of the used complexes bind large and flexible ligands, water-
mediated interactions and extremely flexible receptors. These characteristics still
pose a considerable challenge in the far more explored protein-ligand docking field
(Klebe, 2006) and thus it is difficult to disentangle effects specific to RNA-ligand
docking from problems generic to all known docking methods. Most importantly,
no study which includes validation against known data, identification of novel
ligands and confirmation of the predicted binding mode by structural methods.
To drive molecular docking for RNA targets forward, an amenable system is re-
quired which allows thorough method testing. If such a system offers potential
applications for the discovered ligands, this would be an additional incentive for
investigating this target.
Riboswitches are a class of naturally occurring RNA molecules which have the
potential to serve this purpose. They have been proposed as drug targets (Blount
and Breaker, 2006; Kim et al., 2009; Lee et al., 2009; Ott et al., 2009; Mulhbacher
et al., 2010; Deigan and Ferre-D’Amare, 2011), since they control important
metabolic pathways in bacteria depending on ligand binding, while not occurring
in humans. Therefore in addition to their use as a model system they may be of
therapeutic importance.
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1.3 Riboswitches
1.3.1 General principle
Riboswitches are cis-acting regulatory RNA elements involved in gene regulation.
The typical riboswitch is part of the 5’ leader sequence of mRNA. Located up-
stream of the start codon of the regulated gene, the riboswitch acts as a molecular
switch for the expression of the genes encoded in the particular mRNA. Typically,
the riboswitch is divided into two distinct functional domains, the aptamer and
the expression platform (Tucker and Breaker, 2005). The aptamer domain acts
as the sensory domain, and adopts different conformations in the presence ab-
sence of the specific ligand (Nudler and Mironov, 2004). This information is then
relayed to the expression platform, which converts the signal into an alteration of
gene expression (Nudler and Mironov, 2004; Rieder et al., 2007; Wickiser et al.,
2005; Barrick and Breaker, 2007).
The ligand recognized by the aptamer domain is specific for each riboswitch
and represents a metabolite like adenine (Mandal and Breaker, 2004), guanine
(Batey et al., 2004), S-adenosylmethionine (SAM; Winkler et al. 2003), cobal-
amine (Nahvi et al., 2004) or lysine (Sudarsan et al. 2003b; Fig. 1.2). Ribo-
switches sensing the second messenger cyclic-di-GMP (Fig. 1.2) have also been
reported (Sudarsan et al., 2008).
The aptamer domain can bind the ligand tightly; the in vivo ligand of many
riboswitches has an affinity below KD = 1 µM in in vitro binding experiments
(Montange et al., 2010; Gilbert et al., 2006a; Winkler et al., 2002). Ligand binding
stabilizes a well defined three-dimensional conformation of the aptamer domain.
For many riboswitches the aptamer domain in complex with the ligand has been
crystallized and the three-dimensional structure has been determined (Edwards
and Ferre´-D’Amare´, 2006; Montange and Batey, 2006; Batey et al., 2004; Garst
et al., 2008; Smith et al., 2009, 2011). In the absence of the ligand the structure
of the aptamer domain is usually less defined, and the apo-structure of several
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Figure 1.2: Chemical compounds that are naturally occurring riboswitch ligands.
These include metabolites such as nucleobases (adenine, guanine) as well as amino
acids (lysine, glycine) and the central metabolite SAM. Also the second messenger
cyclic di-GMP was found to be a natural riboswitch ligand.
aptamer domains have been determined by X-ray crystallography. Among these
are the SAM-I riboswitch (Stoddard et al., 2010), the lysine riboswitch (Garst
et al., 2008) and the FMN riboswitch (Vicens et al., 2011).
The expression platform needs to translate the conformational signal from the
aptamer domain into an alteration of gene expression. Two principal classes
of logical switches are conceivable: the ON-switch and the OFF-switch (Fig.
1.3). The OFF-switch prevents gene expression in the ligand bound state while
permitting gene-expression in the ligand-free state (Fig. 1.3 A). The ON-switch
(Fig. 1.3 B) works the opposite way. For both classes examples can be found
occurring in bacteria. Interestingly, the adenine riboswitch of Bacillus subtilis is
an example for an ON-switch (Lemay et al., 2011) while the guanine riboswitch of
B. subtilis acts as an OFF-switch. The aptamer domains of both riboswitches are
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Figure 1.3: Logical types of riboswitches. A: OFF-switch by transcription ter-
mination; DNA is transcribed to RNA which in the absence of ligand results in
formation of an anti-terminator stem loop and subsequent protein expression. In
the case of ligand binding transcription is prevented by a terminator stem loop
and protein production is prevented. B: ON-switch; DNA is transcribed to RNA
and in the case of no ligand binding to the riboswitch the ribosomal binding
site (RBS) is accessible resulting in protein production. In the absence of ligand
ribosomal binding to the mRNA is prevented by sequestering of the RBS into a
stem loop, preventing protein production.
highly similar and their binding sites are virtually identical except for one single
base. This nucleobase, a uridine in the case of the adenine riboswitch, forms
Watson-Crick type hydrogen bonds with the ligand adenine. In the guanine
riboswitch this uridine residue is replaced by a cytidine, also forming Watson-
Crick type hydrogen bonds with the ligand guanine. Whether a riboswitch is part
of the ON- or OFF-switch category is determined by the expression platform.
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1.3.2 Mechanisms of riboswitches
There are two different aspects of gene regulation by riboswitches that need to
be discussed in a mechanistic context; first the mechanism of protein expres-
sion control and second the mechanism of ligand sensing. There are four known
fundamental mechanisms by which riboswitch control can occur:
1. transcription attenuation
2. translation attenuation
3. anti-sense mechanism
4. ribozyme cleavage
A riboswitch employing the transcription attenuation mechanism regulates gene
expression by preventing transcription of the full mRNA in the OFF state of
the switch. This usually happens by formation of a GC-rich terminator stem
(Fig. 1.3 A; Mandal and Breaker 2004; Rodionov et al. 2003), which is followed
by a poly-U stretch (Barrick and Breaker, 2007). This stem causes the RNA-
polymerase to dissociate and results in an incomplete transcript RNA not coding
for a functional protein (Gusarov and Nudler, 1999; Yarnell and Roberts, 1999).
The second mechanism is translation attenuation, mediated via structural chan-
ges in the mRNA that block translation initiation. In the simplest case this is
achieved by sequestering the ribosomal binding site into an element of secondary
structure abolishing ribosome binding (Fig. 1.3 B; Rodionov et al. 2002; Vit-
reschak et al. 2004). Regulation by an antisense transcript is a variation of the
transcription attenuation mechanism. The transcription of the antisense RNA is
controlled by the riboswitch, and the full transcript then inhibits the translation
of the target gene. An example for such a trans-riboswitch is the SreA riboswitch
of Listeria monocytogenesis (Loh et al., 2009). Antisense RNAs in general as reg-
ulatory elements in prokaryotes have been reported and described (Gottesman,
2002).
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Regulation by ribozyme cleavage has up to this date only been found in one
case, the glmS riboswitch/ribozyme. The aptamer domain binds glucosamine-
6-phosphate and utilizes it as a cofactor for self-cleavage (Winkler et al., 2004).
The such cleaved mRNA is subsequently targeted for degradation, preventing
gene expression (Collins et al., 2007).
The first two mechanisms are widely used in riboswitch gene regulation while the
third and fourth are only known to occur in a single example each (Rodionov
et al., 2004; Winkler et al., 2004).
For the mechanism of ligand sensing two scenarios have been observed, where
riboswitches are under thermodynamic or kinetic control. For a riboswitch under
thermodynamic control the fraction of riboswitch in the bound state will be
directly linked to the relative rate of gene expression. The riboswitch operates
in the equilibrium state of ligand binding. An example for a riboswitch under
thermodynamic control is the Vibrio vulnificus add-riboswitch (Rieder et al.,
2007).
However, for other riboswitches the kinetics of ligand binding controls ligand
binding. For the case of regulation by transcription termination the decision
between ON or OFF has to be made before the transcribing RNA polymerase
has progressed past the start codon of the regulated gene. This limited time-
window for genetic regulation can result in riboswitch behavior predominantly
being dependent on the on-rate of ligand binding. Examples of riboswitches
that operate under kinetic control include the B. subtilis pbuE and the xpt-pbuX
purine riboswitches (Gilbert et al., 2006b; Wickiser et al., 2005; Lemay et al.,
2006).
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1.3.3 Distribution of riboswitches in different taxonomic
groups
Prokaryotic riboswitches
Riboswitches have been found in a broad variety of different prokaryotic organ-
isms of very different taxonomic groups, reviewed in Barrick and Breaker 2007.
Some riboswitches like the SAM-I and the thiamine pyrophosphate (TPP) ri-
boswitch are found in most taxonomic groups within prokaryotes, while others
like the purine and the SAM-II riboswitch have been found only in a few groups.
The abundance of riboswitch control in different taxonomic groups varies greatly.
Firmicutes and Fusobacteria display a high number of riboswitches for many dif-
ferent ligands in their genome, while for example in Chlamydia and Spirochetes
only few riboswitches for one or two ligands have been discovered (Barrick and
Breaker, 2007).
Which mechanism is adopted by a particular riboswitch also differs greatly within
species. For example the SAM-I riboswitch acts mainly by transcription atten-
uation in Firmicutes while in Bacterioidetes and γ-proteobacteria it exclusively
utilizes translation attenuation. It seems however, that within different taxo-
nomic groups one or the other mechanism largely predominates. For example, the
γ-proteobacteria almost exclusively utilize translation attenuation in riboswitch-
dependent gene regulation while in firmicutes riboswitches using transcription
attenuation predominate (Barrick and Breaker, 2007).
Eukaryotic riboswitches
The overwhelming majority of riboswitches identified to date were found in
prokaryotic organisms. However, a few riboswitches have been found in eukary-
otes. The first eukaryotic riboswitches identified were the TPP riboswitches in
plants, for example Arabidopsis thaliana and filamentous fungi such as Neurospora
crassa (Sudarsan et al., 2003a). The structure of the A. thaliana TPP riboswitch
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has been solved (Thore et al., 2008). TPP riboswitches have also been identified
in green algae (Croft et al., 2007). In addition to the TPP riboswitch, cytokinin
binding riboswitches have been proposed in A. thaliana (Grojean and Downes,
2010). The regulation mechanisms of eukaryotic riboswitches can include altered
splicing of the mRNA, which is not relevant for prokaryotic riboswitches.
1.3.4 The purine riboswitch
The class of purine riboswitches can be divided in two subclasses, the adenine
and the guanine riboswitches. However, these two subclasses share an extremely
similar aptamer domain, whose specificity for either adenine or guanine is deter-
mined by a single nucleotide. The purine riboswitch aptamer domain consists
of about 70 nucleotides, which upon ligand binding assumes a structurally well
conserved fold based on a three way junction (Fig. 1.4 A). This aptamer domain
was first crystallized in 2004 by two groups independently, with a resolution of
approximately 2 A˚ for both the adenine binding and the guanine binding variant
(Serganov et al., 2004; Batey et al., 2004).
Figure 1.4: The structure of the purine riboswitch. A: Sequence and secondary
structure diagram B: Crystal structure of the purine riboswitch (PDB-file 2g9c)
shown as a cartoon representation.
The crystallographic data confirmed the secondary structure of three helices ar-
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ranged around a central three-way junction (Fig. 1.4 B). The 5′ and 3′ end of
the aptamer domain form the P1 helix which branches into the three-way junc-
tion. The three dimensional structure shows coaxial stacking of the P1 and P3
helices, while the P2 and P3 helices are extending in the same general direction
interacting via their terminal loops. The structures confirmed that the ligand
specificity for either adenine or guanine is determined by the pyrimidine 74. This
nucleotide makes a Watson-Crick-type base pair with the bound purine ligand,
thus specifically binding adenine in case of U74 and guanine in case of C74. The
ligand is bound in a central binding pocket hidden from bulk solvent (Fig. 3.1
B). Held in place by six hydrogen bonds, binding is exceptionally strong for a
molecule this size (only ten non-hydrogen atoms in the case of adenine). Adenine
contains five nitrogen atoms all of which form hydrogen bond contacts with the
aptamer, and the N6-amino group forms two hydrogen bonds, one with U74 and
one with a water molecule located near the only opening of the binding pocket
towards bulk solvent (Serganov et al., 2004). In addition to small nucleobase-like
ligands, it has been shown that the purine riboswitch can also accommodate nu-
cleoside ligands like 2’-deoxyguanosine (Edwards and Batey, 2009). Structural
data show that the binding pocket is enlarged via movement of the A47 and U48
(Fig. 1.5). This implies a degree of flexibility for this riboswitch and supports a
binding model of induced fit upon ligand binding.
It is very important to note that up to date no structure of the purine riboswitch
without a purine in the binding pocket has been determined. All crystal struc-
tures contain an exogenous ligand or, in one case one nucleotide flips its base into
the binding pocket thus mimicking a ligand-bound state (Delfosse et al., 2010).
The folding of the purine riboswitch aptamer domain has been studied extensively
(Lemay et al., 2006; Lin and Thirumalai, 2008; Lee et al., 2010; Leipply and
Draper, 2011). FRET experiments (Lemay et al., 2006) revealed the presence of
three distinct states in solution prior to ligand binding. The first state represents
the unfolded structure with just the helices formed with no tertiary structure. The
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Figure 1.5: Structure of the purine riboswitch (PDB-file 3d2s, blue) bound to
2’-deoxyguanosine (cyan carbon atoms) superpositioned with the 2,4,6-triamino-
pyrimidine bound structure (PDB-file 2g9c, green). The nucleotides A47 and
U48 which move away from the core to generate the space needed for the sugar
moiety of the ligand are highlighted with arrows.
second state, the intermediate state has P1 and P3 stacked but no interaction
with P2, while the third state, the folded state has P1 and P3 stacked and the
loop-loop interaction between P2 and P3 formed. The ligand can bind to the
folded structure, thereby stabilizing it, resulting in the formation of a stable
pseudoknot conformation of the three-way junction.
1.3.5 The SAM-I riboswitch
Seven different riboswitches have been identified for the ligand SAM (Winkler
et al., 2003; Corbino et al., 2005; Lu et al., 2008; Weinberg et al., 2008; Poiata
et al., 2009). The SAM riboswitches contain different aptamer domains that
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are structurally diverse. Crystal structures determined for SAM-I, SAM-II and
SAM-III illustrate this (Fig. 1.6). The binding mode of the SAM and the ligand
recognition patterns vary significantly between the different classes (Montange
and Batey, 2006; Gilbert et al., 2008; Lu et al., 2008).
Figure 1.6: The diversity of SAM-binding aptamer domains. The structures of
the SAM-I, SAM-II and SAM-III have been solved to date. A: Structure of
the SAM-I riboswitch (PDB-file 2gis), B: Structure of the SAM-II riboswitch
(PDB-file 2qwy), C: Structure of the SAM-III riboswitch (PDB-file 3e5c). All
riboswitches are displayed in a cartoon representation. The SAM ligand is shown
with cyan carbon atoms.
The structural diversity of SAM-aptamers is also reflected in the different sizes
of the aptamer domains from the various classes of SAM-riboswitches. While the
SAM-I aptamer domain contains approximately 100-150 nucleotides SAM-II and
SAM-III are significantly smaller with only 40-65 nucleotides (Fig. 1.6). Over
the whole class SAM-recognizing aptamers can differ in size by up to a factor of
five (Wang and Breaker, 2008).
The SAM-I riboswitch was originally discovered in gram-positive bacteria, espe-
cially B. subtilis, as a domain of conserved sequence, called the S-box (Grundy
and Henkin, 1998), even though riboswitches were unknown at the time and the
regulation of gene expression was hypothesized to depend on ”some unknown
factor” (Grundy and Henkin, 1998). The S-box motif was found eleven times
in the B. subtilis genome regulating eleven operons comprising 25 genes in total.
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These genes are involved in sulfur metabolism and the biosynthesis of methionine
and SAM (Tomsic et al., 2008). The description of the S-box motif as a ribo-
switch, which then became the SAM riboswitch was reported in 2003 (Winkler
et al., 2003). Subsequent discovery of unrelated riboswitches that also bind and
recognize SAM led to renaming this the SAM-I riboswitch. The natural ligand of
this riboswitch is SAM, a central metabolite in prokaryotes as well as eukaryotes
(Loenen, 2006; Grillo and Colombatto, 2008).
SAM-based gene regulation operates by transcription termination, which occurs
in the ligand-bound state making the SAM-I riboswitch an OFF-switch (Winkler
et al., 2003). The ligand specificity of the aptamer domain has been investigated
(Winkler et al., 2003; Lim et al., 2006; Montange et al., 2010). SAM has a
submicromolar binding affinity (5nM for the B. subtilis yitJ riboswitch) and the
chemically very similar S-adenosylhomocysteine (SAH) typically has an over 100
fold higher dissociation constant (Winkler et al., 2003; Montange et al., 2010).
The secondary structure of the SAM-I riboswitch is organized by a central four-
way junction from which all four helices branch (Fig. 1.7 A). Similar to the purine
riboswitch the ends form the P1 helix and the other helices P2-P4 (5’ to 3’) are
stem loops (Montange and Batey, 2006) while helix P1 is unterminated.
However, P2 and P3 are not simple stem loops but contain several unpaired
nucleotides. In the case of P2 the helix is interrupted by a k-turn motif (see
below and Fig. 1.7 A) and the distal part of the helix is called P2a. The P3 helix
contains a bulge located at its center.
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Figure 1.7: Structure overview for the SAM-I riboswitch. A: Schematic repre-
sentation of the secondary structure. B: Cartoon representation of the SAM-I
riboswitch. The SAM-ligand is displayed in cyan carbon atoms.
A crystal structure was first determined for the Thermoanaerobacter tencongesis
SAM-I riboswitch (Montange and Batey, 2006). The SAM binding pocket is
located in the core of the folded aptamer (Fig. 1.7 B), the SAM ligand assumes
a highly compact conformation with the methionine moiety stacking back onto
the adenine moiety (Fig. 1.8). The ligand interacts with the binding pocket via
multiple hydrogen bonds tethering each part of the ligand to the pocket (Fig.
1.8). The adenine moiety is bound by A45 and U57, which are prevented from
forming a standard Watson-Crick base pair. A45 and U57 form hydrogen bonds
with the N1, N6 and N7 nitrogen atom of the SAM, thus utilizing both the
Hoogsteen and the Watson-Crick edges. The ribose moiety of the SAM forms
two hydrogen bonds, one from the 2’-hydroxyl group to the O4’-ring oxygen of
the C47 ribose and one from the 3’-hydroxyl group to the U7 O4’-ring oxygen.
The methionine moiety is held in place via hydrogen bonds from the carboxyl
group to the Watson-Crick edge of G11 and the N2 amino group of G58. Also the
methionine amino group of the SAM ligand hydrogen bonds to the 2’-hydroxyl
group and N3 of G58. These multiple hydrogen bonds together with a good
shape complementarity of the ligand and the binding pocket result in a sub-
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Figure 1.8: Wall-eyed stereo view of the SAM ligand (cyan carbon atoms) bound
to the SAM-I riboswitch (grey cartoon). The nucleotides interacting with the
ligand are shown with green carbon atoms and the hydrogen bonds between ligand
and riboswitch are highlighted in black dashed lines. The figure illustrates the
tight interaction of all parts of the SAM ligand with the riboswitch nucleotides.
micromolar (approximately 300 nM) affinity of SAM for the T. tengcongensis
SAM-I riboswitch.
The SAM-I riboswitch was also crystallized in the absence of ligand (Stoddard
et al., 2010). The apo structure is highly similar to the SAM-bound structure
and the most prominent difference is the conformation of A46. This nucleotide is
located outside of the binding pocket in the presence of the SAM ligand but flips
into the binding pocket in the absence of ligand. The A46 in the binding pocket
forms hydrogen bonds to both A45 and U57 (Fig. 1.9).
1.4 k-turns
As mentioned above, the SAM-I riboswitch contains a kink-turn (k-turn) motif in
the P2 helix. The k-turn motif was first described about 10 years ago (Klein et al.,
2001) as a repeated structural RNA motif found in ribosomal crystal structures
(Ban et al., 2000; Schluenzen et al., 2000; Wimberly et al., 2000). The k-turn is a
conserved intra-helical three-dimensional structural motif, that introduces a kink
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Figure 1.9: Superposition of the SAM-bound structure (PDB-file 2gis) and the
apo-structure of the SAM-I riboswitch. The SAM-bound structure is displayed in
grey cartoon representation and the apostructure in beige cartoon representation.
The key nucleotides and the ligand are shown as sticks. The SAM ligand is shown
in cyan carbon atoms, A45 & U57 in green carbon atoms for the SAM-bound
structure and in amber carbon atoms for the apo structure. The A46 is shown
in red for the SAM-bound structure and in dark blue for the apo structure.
into an RNA helix with an approximate included angle of 60◦ between the helix
arms. The nomenclature is used as in (Liu and Lilley, 2007) and a schematic is
displayed in Figure 1.10. It can be divided into three parts. The central part
consists of 2-4 unpaired bases in one strand which is termed the bulged strand
(b-strand). These nucleotides are named 5’ to 3’ as L1 to Ln in case of an n-base
bulge. The helix to the 5’ side of the bulge is termed the canonical helix (C-
helix), since it consists of standard Watson-Crick base pairs. To the other side
of the bulge the non-canonical helix (NC-helix) contains 2-4 non-standard base
pairs before becoming a helix of standard base pairs. It is the bulge region and
the NC-helix that mainly form the characteristic interactions in k-turns.
The structural data on multiple examples of the k-turn motif facilitated an anal-
ysis of the interactions stabilizing the k-turn fold ( Fig. 1.11) (Turner and Lilley,
2008). The two base pairs adjacent to the bulge are conserved A-G base pairs with
G1b and A2b pairing to A1n and G2n respectively in a trans Hoogsteen-sugar
edge interaction. Another conserved interaction is a hydrogen bond between the
L1-2’ hydroxyl and the A1n-N1, which has been shown to be essential for k-turn
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Figure 1.10: Schematic representation of a k-turn with the nomenclature for the
nucleotides as used here.
folding (Liu and Lilley, 2007). Also the 2’-hydroxyl group of L2 and L3 form
hydrogen bonds to the non-bridging proS phosphate oxygens in their proximity.
After their first description, k-turns have been found in multiple RNA species
of different types and have been collected in a web-based database (Schroeder
et al., 2010). These RNAs include the 23S and 16S rRNA (Klein et al., 2001),
riboswitches (Montange and Batey, 2006; Blouin and Lafontaine, 2007), snoR-
NAs (Cle´ry et al., 2007; Li and Ye, 2006), mRNAs in addition to riboswitches
(Chao and Williamson, 2004) and snRNAs (Woz´niak et al., 2005). All of the
aforementioned RNAs have structurally confirmed examples but there are many
more examples of putative k-turns that have not been verified yet. k-turns appear
to be an important structural feature of ribosomes (Klein et al., 2001), and are
recognized by a number of k-turn binding proteins, including L7Ae (Hamma and
Ferre´-D’Amare´, 2004), S7, S11 (Dunkle et al., 2011) and L24.
k-turns in a simple duplex adopt the tightly kinked conformation only in the
presence of metal ions (Goody et al., 2004; Matsumura et al., 2003). The best-
studied example is the Haloarcula marismortui Kt-7 from the 23S ribosomal
subunit and this k-turn has been used as a model system to characterize the
motif. When an RNA duplex containing Kt-7 and and labeled with fluorescein
and Cy3 is titrated with metal ions, magnesium ions induce folding of Kt-7 with
[Mg2+] 1
2
= 80µM while sodium ions induce folding at much higher concentrations
as reflected in [Na+] 1
2
= 30mM (Liu and Lilley, 2007). Folding isotherms are
well fitted as a two state process with a Hill coefficient of nHill ≈ 1. These data
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Figure 1.11: Wall-eyed stereo view of the H. marismortui Kt-7 showing the key
interactions for k-turn formation. The hydrogen bonds of the two G-A pairs
are shown in blue, the crucial hydrogen bond from the O2’ of L1 to N1 of A1n
in red and the hydrogen bonds form the O2’ of L2 and L3 to the neighboring
non-bridging proS oxygens are shown in red.
indicate that metal ions act as diffuse counter ions that neutralize the phosphate
charge to allow close approach of the backbone in the folded state, rather than
requiring metal ion binding at specific sites. Furthermore, it was shown that
k-turns in isolation can be folded by k-turn binding proteins in the absence of
metal ions (Turner et al., 2005; Woz´niak et al., 2005). The ubiquity of k-turn
motifs in key biological RNAs emphasizes the importance of an understanding
of k-turn structure and function on a molecular level. The binding of k-turns to
their cognate proteins is likely to be an important event in ribosome biogenesis.
1.5 Objectives
1.5.1 Development and validation of a method for RNA
ligand docking
In order to advance the field of RNA-ligand docking, a method was developed
and tested using a suitable model system. The Bacillus subtilis xpt-pbuX guanine
riboswitch mutant C74U (GRA) was selected as a model system because of its
computational and experimental tractability. Additionally this system offers a
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wealth of published binding and structural data. The binding pocket of the purine
riboswitch is small, completely buried from bulk solvent and does not contain
any formal charge. These characteristics are similar to those of model binding
pockets used for method development and validation in the protein docking field
(Wei et al., 2002; Rosenfeld et al., 2003; Brenk et al., 2006). These features
were expected to facilitate interpretation of the results and comparison to the
protein-ligand docking field. Also the experimental amenability of the system
would enable validation of computational results and thus provide a solid base
for later generalization. A comprehensive investigation of the performance of the
chosen computational approach both by retrospective and prospective methods
was attempted. To date this is the first study of RNA-ligand docking to include
high-resolution structures of predicted RNA-ligand complexes.
The high solubility of adenine compared to guanine makes the adenine-responsive
C74U purine riboswitch a suitable system for the exploration of RNA-ligand
docking.
1.5.2 Virtual ligand screening of the SAM-I riboswitch
The SAM-I riboswitch occurs with very similar sequence multiple times in the
genome of gram positive bacteria such as B. subtilis, B. anthracis and B. cereus,
regulating essential metabolic pathways. This makes this riboswitch an ideal tar-
get for drug design, occurring both in pathogenic and non-pathogenic organisms.
Any compound binding to the SAM-I riboswitch with high affinity and thereby
perturbing gene expression would affect multiple protein targets. A virtual ligand
screening was performed to identify new ligands.
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1.5.3 Study of the sequence dependence of k-turn folding
in context of the SAM-I riboswitch
The SAM-I riboswitch contains a k-turn in its P2 helix, it is relatively easy to
crystallize and SAM-binding is an indicator of folding. Therefore, this riboswitch
offers an opportunity to study k-turn folding in an RNA with long range tertiary
interactions. The sequence-dependent folding of the k-turn from this riboswitch
was investigated in isolation and in context of the SAM-I riboswitch in order
to elucidate the contribution of tertiary interactions to k-turn folding. Data
obtained from folding studies using FRET measurements and calorimetry were
backed up with structural evidence from X-ray crystallography.
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Chapter 2
Materials and Methods
2.1 Virtual ligand screening / molecular dock-
ing
2.1.1 Receptor preparation
The coordinates of the receptor molecules used, PDB files 2g9c (Gilbert et al.,
2006a) for the GRA and 2gis (Montange and Batey, 2006) for the SAM-I ri-
boswitch, were obtained from the PDB (www.pdb.org). Hydrogen atoms were
added using the Sybyl software (Tripos). The positions of these hydrogens were
subsequently minimized using the MAB force field (Gerber and Mu¨ller, 1995) as
implemented in Moloc (Gerber molecular design) while keeping all non-hydrogen
atoms rigid. Afterwards all atoms not part of the final receptor setup (all atoms
not part of the RNA and potential water molecules kept for docking) were re-
moved. The ligand binding site was defined via a sphere set, which was calculated
according to the principles described below. This sphere set was based on a cu-
bic grid and the coordinates of the original ligand. The sphere set serves two
purposes during docking:
1. it defines the binding site and is used to determine the area within the bind-
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ing site with a reduced dielectric constant for calculating the electrostatic
potential
2. during docking ligand atoms are matched with the spheres to generate
potential binding modes
Therefore, different sphere sets can be used during receptor preparation and
docking.
For docking of GRA the same sphere set was used for receptor preparation and
docking. The distance between neighboring grid points was ≈1.5 A˚ and the grid
extended 2 A˚ around the original ligand. For the SAM-I riboswitch docking, two
different sphere sets were used. The sphere set used for receptor preparation and
the docking of the SAM-analogues extended 5 A˚ around the original SAM-ligand
and neighboring grid points were ≈ 2A˚ apart. For docking, a smaller sphere set,
1.5 A˚ around the adenine moiety of the SAM ligand with neighboring grid points
≈ 2 A˚ apart, was used. Partial charges for all receptor atoms were obtained
from the AMBER99 force field parametrization (Wang et al., 2000). The charges
of the phosphate oxygen atoms were modified to obtain a resulting net charge
of zero per nucleotide, thus mimicking charge screening by diffuse counter ions
(Detering and Varani, 2004; Moitessier et al., 2006). The electrostatic potential
of the receptor was calculated using DelPhi (Nicholls and Honig, 1991), with an
internal dielectric constant of 2 and an external dielectric constant of 78. The
van der Waals energy map was calculated using the DOCK utility CHEMGRID
and the excluded volume map using the DOCK utility SOLVMAP (Mysinger and
Shoichet, 2010).
2.1.2 Sphere set generation
Originally, DOCK 3.5.54 and the accompanying scripts provided a sphere set
consisting of the atoms of the original ligand in the crystal structure. In case of
no original ligand being present, a substitute had to be provided manually. This
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procedure introduces a bias towards the correct binding mode for the original
ligand and ligands based on the scaffold of the original ligand. To avoid this
problem and to generate sphere sets that define the binding site well, an algorithm
was developed that generates a regular lattice of spheres with the lattice axes
derived from the original ligand geometry. From this lattice of spheres, only
spheres around the original ligand and not too close to any receptor atoms were
included in the final sphere set for docking (Fig. 2.1).
Figure 2.1: Example sphere set generated for docking. Yellow carbon atoms:
ligand from the PDB-file used for docking (2,4,6-triaminopyrimidine). Cyan:
Spheres generated based on that ligand. The spheres are arranged on a simple
cubic crystal lattice. The lattice orientation was based on the ligand geometry,
resulting in one lattice vector being orthogonal to the ligand plane. Only spheres
not clashing with any RNA atoms were kept, so the sphere set reflects the shape
of the binding site.
2.1.3 Small molecule preparation
From the in-house databank of commercially available compounds with precalcu-
lated physicochemical properties (Brenk et al., 2008), the screening sets were
assembled by filtering for compounds with desirable properties (as described
in the corresponding results chapters). The training set for the GRA and the
SAM analogues for the SAM-I riboswitch were generated manually in SMILES
format (Weininger, 1988). The protocol for the preparation of small molecu-
les for docking was similar to the one described in (Mpamhanga et al., 2009).
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Protonation states and tautomeric states were calculated using in-house scripts
based on the OEToolkit (Openeye, Santa Fe, NM). Three-dimensional coordi-
nates and low energy conformations were calculated using OMEGA2 (Openeye,
Santa Fe, NM). Partial charges and desolvation energy were calculated using AM-
SOL (http://comp.chem.umn.edu/amsol/; Wei et al. 2002; Brenk et al. 2006).
Finally, molecules were aligned on their ring systems and stored in a hierarchical
format (Wei et al., 2002).
2.1.4 Molecular docking
After receptor and small molecules preparation docking was performed using
DOCK 3.5.54 (Lorber and Shoichet, 1998; Wei et al., 2002; Mysinger and Shoi-
chet, 2010). Sampling parameters were:
• receptor and ligand bins were set to 0.5 A˚
• overlap bins were 0.4 A˚
• distance tolerance for ligand atoms and receptor matching sites ranging
from 1.1 A˚ to 1.2 A˚
Only docking poses not placing ligand atoms in the area occupied by the receptor
were scored for electrostatic interaction energy, van der Waals energy and des-
olvation energy. Only the best-scoring representation in terms of docking pose,
as well as protonation and tautomerization states, was stored in the resulting
output files.
2.1.5 Docking analysis, pharmacophore filtering and mo-
lecular graphics
Docking results were visualized and analyzed with the Sybyl software (Tripos).
Pharmacophore filtering was also carried out using the Sybyl interface. The
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pharmacophore was built in Sybyl by placing hydrogen bond acceptor and donor
functionalities at the desired locations. The filtering was performed using the
UNITY module (Tripos). All diagrams of molecular structures were generated
in PyMOL (http://pymol.org). Two-dimensional chemical structures were gen-
erated using Symyx Draw 3.3 (Symyx solutions).
2.2 RNA synthesis and purification
2.2.1 Synthesis of fluorescently labeled RNAs
The RNA oligonucleotides were synthesized via t-BDMS phosphoramidite chem-
istry (Beaucage and Caruthers, 1981) as described previously (Wilson et al.,
2001). Fluorescein and Cy3-conjugated oligonucleotides were attached at the
5’-termini as phosphoramidites during synthesis. The oligoribonucleotides were
deprotected in 25% ethanol / ammonia solution at 65 ◦C for 1h and dried. Sub-
sequently, oligoribonucleotides were dissolved in 300 µl 1M tetrabutylammonium
fluoride in tetrahydrofuran to remove the t-BDMS protecting groups and agi-
tated at 20 ◦C for 16h prior to desalting using a G25 Sephadex column (NAP
columns, Pharmacia) and ethanol precipitation. All oligonucleotides were pu-
rified by denaturing polyacrylamide gel electrophoreses and recovered from gel
fragments by electroelution or diffusion followed by an ethanol precipitation. The
fluorescently-labeled RNA was purified by reversed-phase HPLC on a C18 column
(ACE10, Advanced Chromatography Technologies) using an acetonitrile gradi-
ent with an aqueous phase of 100mM triethylammonium acetate (pH 7.0). The
duplex species were annealed in 50 mM Tris-HCl (pH 7.5), 25 mM NaCl by slow
cooling from 90 ◦C to 4 ◦C and purified by electrophoresis.
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2.2.2 In vitro transcription of riboswitch aptamer do-
mains
RNA for both riboswitches was transcribed in vitro from templates generated by
PCR. The primers used for the PCR were as follows, written from 5’ to 3’:
• generic 5’ primer: GCGCGCGAATTCTAATACGACTCACTATAG
• 3’ primer for SAM-I riboswitch: CGGCTCATCTTTCAACGTTTCCGCT
• 3’ primer for the GRA: TGGACATAATCGGACATTTACGGTGCCCGG
The final PCR mixture (typically 1ml final volume) contained: 20 mM Tris-HCl
(pH 8.8), 10 mM (NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1 % Triton X-100,
0.2 mM each dNTPs, 1 µM each primer, 600 ng
ml
template plasmid and 1 U
ml
Taq
DNA polymerase (prepared in house). The plasmids containing the riboswitch
sequences (containing the GRA and the T. tengcongensis SAM-I U34C/A94G se-
quences) were generously supplied by Robert T. Batey. PCR was then performed
in a thermocycler using the following regime: 5min 94 ◦C initial denaturation,
then 25 cycles of 30 sec 94 ◦C denaturation, 30 sec 55 ◦C annealing and 30 sec
72 ◦C extension, followed by a final 7 min elongation step at 72 ◦C.
The transcription reaction itself (typically 12.5 ml final volume) contained 40 mM
Tris-HCl (pH 8.0), 4 mM each NTP (Sigma), 32 mM MgCl2, 10 mM DTT, 3.2
mM spermidine, 0.01 % Triton X-100, 0.25 mg
ml
T7 RNA polymerase (prepared
in-house), 8.0 % (v/v) DNA template from the PCR reaction described above
and 0.1 U
ml
inorganic pyrophosphatase (Sigma). Transcriptions were allowed to
proceed for 3h at 37 ◦ C and precipitated with 3 volumes of cold ethanol. Typ-
ically transcriptions were of 12.5 ml volume, and the template PCR accordingly
of 1 ml volume.
The precipitated transcription reactions were subsequently purified by denaturing
polyacrylamide gel electrophoresis. The gels contained 12 % polyarcyrlamide
(19:1), 90 mM Tris borate (pH 8.3), 10 mM EDTA and 7 M urea. The RNA was
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visualised by UV shadowing and the product band was cut out. The RNA was
then electro-eluted in a 3000 Da molecular weight cut-off dialysis tube against
90 mM Tris borate (pH 8.3) and 10 mM EDTA overnight at 4 ◦C. RNA was
then concentrated using 3000 Da molecular weight cut-off spin concentrators
and quantified by UV absorbance. The molar extinction coefficients used were
260nm,GRA = 680000
1
M cm
and 260nm,SAM−I = 850000 1M cm for the GRA and the
SAM-I riboswitch, respectively.
2.3 Binding assays
2.3.1 Fluorescence binding assay for the GRA
The fluorescence spectra for the binding assay were recorded on an SLM-Aminco
8100 flourimeter. The sample buffer consisted of 50 mM Tris HCl (pH 8.3),
100 mM KCl and 10 mM MgCl2. The spectra of the fluorophore 2-aminopurine
were collected from 330 to 450 nm with an excitation wavelength of 300 nm
and corrected for lamp fluctuations and instrumental variations. 2-aminopurine
fluorescence was determined as the integral of the collected spectra.
The binding constant of the fluorophore (compound 3 / 2-aminopurine, Tab. 3.2)
was determined first. For this RNA was titrated into a solution containing 200
nM 2-aminopurine in sample buffer. The free 2-aminopurine concentration was
calculated and fitted to a simple two state binding model, resulting in a binding
constant of KL = 140 nM.
Competition experiments were carried out by titrating ligand into a solution of
fluorophore and GRA. Initially, a 2-aminopurine spectrum (c=213 nM) was col-
lected prior to adding GRA to a final concentration of 243 nM RNA and 200 nM
fluorophore. After RNA addition, the solution was left to equilibrate for 10 min
and a spectrum was recorded. Subsequently, competition ligand was incremen-
tally added to a final concentration of at least 1.2 mM (except for compound 25
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where the maximum concentration was 0. 68mM due to limited solubility). After
each addition, the sample was left to equilibrate for 3 min prior to measurement
of a spectrum. This time was estimated to be sufficient for equilibration based on
reported data on the folding kinetics for the purine riboswitch (Buck et al., 2007)
Data were processed and analyzed in Excel (Microsoft). Free 2-aminopurine con-
centration was fitted to the following binding model with two complexes and
dilution effects were taken into account (Yan et al., 2005):
R3 + aR2 + bR−KLKDRtot = 0 (2.1)
where
a = Ltot +Xtot +KL +KD −Rtot (2.2)
b = KDLtot +KLXtot +KLKD −Rtot(KL +KD) (2.3)
In these equations, R is the concentration of unbound RNA, Rtot the total RNA
concentration, Ltot the total 2-aminopurine concentration, Xtot the total con-
centration of test compound (competition ligand), KL the binding constant of
2-aminopurine, and KD the binding constant of the test compound. All param-
eters except R and KD are known at the start of the experiment. R is obtained
from the fluorescence reading using the known KL. KD can then be obtained
from minimizing
Φ =
∑
χi (2.4)
where, for the ith data point,
χi = R
3 + aR2 + bR−KLKDRtot (2.5)
The obtained binding constants were averaged from three measurements and
rounded to a precision of 0.01 mM (0.001 mM for compound 5).
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2.3.2 ITC measurements for the SAM-I riboswitch with
varied k-turn sequences
ITC measurements for the SAM-I riboswitch with varied k-turn sequences were
carried out at 30 ◦C using the MicroCal VP-ITC instrument (GE Healthcare).
The protocol was similar to that described in (Montange et al., 2010). The
SAM-I sequence was GGCUUAUCAAGAGAGGUGGAGGGACUGGCCCGAC-
GAAACCCGGCAACCAGAAAUGGUGCCAAUUCCUGCAGCGGAAACGUU
GAAAGAUGAGCCG, which carries the U34C/A94U mutation and is defined
here as the natural sequence. Modifications in the k-turn were inserted into a
plasmid bearing this sequence by site-directed mutagenesis. During the titration,
a solution of 100 µM SAM in sample buffer was injected into the cell containing
10 µM SAM-I riboswitch in sample buffer. The sample buffer contained 40 mM
K-HEPES (pH 7.5), 100 mM KCl and 10 mM MgCl2. Following an initial 1 µl
injection 35 injections of 8 µl were performed. The resulting calorimetric data
were analyzed using the MicroCal Origin software and fitted to a single-site bind-
ing model. Each titration was performed in triplicate and the obtained fitting
parameters were averaged. Free energy and the dissociation constant for SAM
were calculated from:
∆H◦ − T∆S◦ = ∆G◦ = −RTlnKD (2.6)
where R is the gas constant and T is the temperature in Kelvin.
2.3.3 Competition ITC measurements for the SAM-I ri-
boswitch
The competition ITC measurements to determine binding of the screening com-
pounds to the SAM-I riboswitch were conducted using the VP-ITC calorimeter
from Microcal. Sample buffer was prepared by adding 2 %(v/v) of 100 mM com-
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pound in DMSO to the basic ITC buffer described above (40 mM K-HEPES (pH
7.5), 100 mM KCl, 10 mM MgCl2), resulting in a final concentration of 2 mM for
the competition ligand. For the reference measurement in the absence of compe-
tition ligand DMSO only was used. RNA was buffer-exchanged by centrifugation
five times in a microconcentrator and rediluting with sample buffer, obtaining
a final concentration of about 200 µM. RNA was then diluted down to a final
concentration of 5 µM and inserted into the cell. RNA was quantified prior to
buffer exchange, since the presence of compound did not allow accurate RNA
quantification due to overlapping absorbance. The SAM solution for the syringe
was prepared by adding 10 µl of 10 mM SAM solution to 2 ml of sample buffer
containing the competition ligand. For the titration, 35 8 µl injections were per-
formed following an initial 1 µl injection. The raw data were analyzed using the
MicroCal Origin software to obtain the heat evolved for each injection. These
data were then fitted in Excel to a single state binding model derived from the
model used in the original software. The fitting function supplied by the software
assumes the following model:
∆H = 0.5Vcell∆H
◦
1 + 1− XtMt − nKaMt√
(1 + Xt
Mt
− n
KaMt
)2 − 4Mt
 (2.7)
where Vcell is the volume of the cell, Ka the apparent association constant of
SAM, Xt the concentration of SAM in the cell and Mt the concentration of RNA
in the cell. This model requires ∆H ≈ 0 for large Xt
Mt
(towards the end of the
titration), however due to minute differences in buffer composition between cell
and syringe, there is a residual ∆Hbuff . Therefore, the model was modified to
account for this:
∆H = 0.5Vcell∆H
◦
1 + 1− XtMt − nKaMt√
(1 + Xt
Mt
− n
KaMt
)2 − 4Mt
+ ∆Hbuff (2.8)
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All titrations could be fitted to this modified model. Due to high requirement
of RNA and ligand, titrations were carried out only once per ligand. A binding
constant for the competition ligand was calculated from the apparent binding
constant of SAM in the absence and presence of competition ligand using the
following formula (Zhang and Zhang, 1998):
KcompligD =
clig(
KSAM+ligD
KSAMD
− 1
) (2.9)
2.3.4 FRET folding assay
Absorption spectra were measured in 90mM Tris-borate (pH 8.3) in 120 µl vol-
umes using a NanoDrop 2000C spectrophotometer (Thermo Scientific). Spectra
were deconvoluted using a corresponding RNA species labeled only with Cy3.
Fluorophore absorption ratios were calculated using a MATLAB program. Flu-
orescence spectra were recorded in 90 mM Tris-borate (pH 8.3) at 4 ◦C using
an SLM-Aminco 8100 fluorimeter. Spectra were corrected for lamp fluctuations
and instrumental variations and polarization artifacts were avoided by setting the
excitation and emission polarizers crossed at 54.7 ◦. Values of FRET efficiency
were measured using the acceptor normalization method (Clegg et al., 1992) im-
plemented in MATLAB. FRET efficiency as a function of metal ion concentration
was fitted to a two state model for ion-induced folding:
EFRET = E0 + ∆EFRET
(
Ka[M ]
n
1 +Ka[M ]n
)
(2.10)
where E0 is the FRET efficiency of the RNA in the absence of added metal
ions, ∆EFRET the increase in FRET efficiency between start and saturation. [M]
is the Mg2+ ion concentration, Ka the apparent association constant for metal
ion binding and n the Hill coefficient. Data were fitted in KaleidaGraph to
this equation by nonlinear regression and the metal concentration at which the
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transition was half complete is given by:
[M ] 1
2
=
(
1
Ka
) 1
n
(2.11)
2.4 Crystallography and structure determina-
tion
2.4.1 Crystallization
All crystals were grown using the hanging drop method in 24-well plates on VDX
slides (Hampton Research). RNA was buffer-exchanged and concentrated to give
a 400 µM solution in sample buffer (10 mM K-HEPES (pH 7.5) for the GRA and
40 mM Na-cacodylate (pH 7.0) for the SAM-I riboswitch) with ligand present.
Crystals were then grown in drops generated by mixing 1 µl of RNA solution with
1 µl of mother liquor. Crystal drops were then seeded using the microseeding
technique. Seed stocks were obtained from crystals grown unseeded. For the
GRA, these were grown with 2,6-diaminopurine as the ligand, for the SAM-I
riboswitch the natural sequence was readily crystallized with SAM. Obtained
crystals from three drops were then combined with 50 µl of mother liquor and
mixed thoroughly. All crystal trays were stored at ≈ 20 ◦C.
Crystallization of GRA-complexes
The sample buffer for the GRA contained 1mM of the respective ligand. The
mother liquor for the conditions yielding the crystal for data collection contained:
1. 2-aminopurine complex (compound 3, Tab. 3.2): 320 mM ammonium ac-
etate, 12 mM cobalt hexammine, 17.5 % PEG 3000, 10 mM K-HEPES (pH
7.5)
2. N6-methyladenine complex (compound 15, Tab. 3.2): 440 mM ammonium
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acetate, 12 mM cobalt hexammine, 20.0 % PEG 3000, 10 mM K-HEPES
(pH 7.5)
3. complex with compound 24 (Tab. 3.3): 560 mM ammonium acetate, 12
mM cobalt hexammine, 22.5 % PEG 4000, 10 mM K-HEPES (pH 7.5)
4. complex with compound 26 (Tab. 3.3): 800 mM ammonium acetate, 12
mM cobalt hexammine, 25.0 % PEG 4000, 10 mM K-HEPES (pH 7.5)
5. complex with compound 27 (Tab. 3.3): 800 mM ammonium acetate, 12
mM cobalt hexammine, 25.0 % PEG 3000, 10 mM K-HEPES (pH 7.5)
Crystallization of the SAM-I riboswitch
The sample buffer contained 1mM SAM. The mother liquor for the crystals used
for data collection contained:
1. G2nA variant: 40 mM Na-cacodylate (pH 7.0), 16 mM spermine-HCl, 10
mM MgCl2, 80 mM KCl, 14 %(v/v) MPD
2. G2nU/G3nU variant: 40 mM Na-cacodylate (pH 7.0), 12 mM spermine-
HCl, 5 mM BaCl2, 80 mM KCl, 12 %(v/v) MPD
2.4.2 Data collection, processing and structure modeling
For the structure of GRA, in complex with compound 15, data were collected at
the Diamond Light Source beamline I03 (Didcot, UK). For all other structures of
GRA data were collected at beamline ID14-1 at the ESRF (Grenoble, France).
Data were indexed, integrated and scaled using HKL2000 (Otwinowski and Mi-
nor, 1997). Structures were solved using MOLREP (Vagin and Teplyakov, 1997)
from the CCP4 suite of programs (CCP4, 1994) using PDB-file 2g9c as a starting
model. Refinement was performed using REFMAC5 (Vagin et al., 2004) from the
CCP4 suite of programs. Model building was performed in COOT (Emsley and
48
Cowtan, 2004; Emsley et al., 2010). Ligand topology files were generated using
the PRODRG webserver (Schu¨ttelkopf and van Aalten, 2004). All coordinates,
except for the 2-aminopurine complex, were deposited in the protein data bank
with accession codes 2xo0,2xo1,2xnw and 2xnz.
For the SAM-I riboswitch, the data on the G2nA variant were collected at beam-
line BM14 at the ESRF (Grenoble, France). Data were indexed, integrated and
scaled using HKL2000 (Otwinowski and Minor, 1997). For the G2nU/G3nU
variant, data were collected at beamline ID14-4 at the ESRF (Grenoble, France).
Data were indexed and scaled using MOSFLM/Scala (Leslie, 2006; Battye et al.,
2011) from the CCP4 suite of programs. Both structures were solved using MOL-
REP (Vagin and Teplyakov, 1997) and refinement was carried out in REFMAC5
(Vagin et al., 2004). Model building was performed in COOT (Emsley and Cow-
tan, 2004; Emsley et al., 2010). Composite omit maps were calculated using
Autobuild in PHENIX (Adams et al., 2010). Finally structures were deposited
in the PDB (accession codes 2ygh and 2ydh).
49
Chapter 3
Virtual screening for ligands for
the xpt-pbuX guanine riboswitch
C74U mutant from B. subtilis
3.1 Overview
To develop and validate a method for RNA-ligand docking, a model system was
chosen. The DOCK 3.5.54 software was adapted to perform the RNA-ligand
docking and the approach was validated by comparison of docking results for
known ligands and non-binders with the published data. Subsequently, a large set
of compounds was screened to identify potential novel binders. These candidate
compounds were then tested experimentally and for a subset of the confirmed
binding compounds the binding mode was determined by X-ray crystallography.
The results are discussed with respect to the implications for RNA-docking and
molecular docking in general.
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3.2 Results
3.2.1 Screening of a test set of known binders and non-
binders
Application of DOCK 3.5.54 to RNA targets
To advance the field of RNA-ligand docking the GRA was chosen as a test system.
At the outset of the study, DOCK 3.5.54 had only been applied to protein targets
and DOCK 3.5.54 was lacking the necessary parameter files for the monomeric
subunits of RNA. The required parameters were atom type and partial charge for
each atom. The atom types were assigned manually and the partial charges were
obtained from the AMBER99 force field (Wang et al., 2000). RNA naturally is
a poly-anion in solution, which requires counter ions to maintain local electro-
neutrality (as reviewed in Draper 2004). To reflect this, the partial charges for the
phosphate oxygens were adjusted so that for each monomeric subunit the sum of
partial charges was zero, as it was reported in previous studies (Moitessier et al.,
2006; Detering and Varani, 2004).
To probe the setup described above, a test set of compounds with known binding
properties was assembled from the literature. This test set was to include both
binders and non-binders and comprised all compounds with published binding
properties for that receptor at this time. The data set was assembled from two
publications (Mandal and Breaker, 2004; Gilbert et al., 2006a). Gilbert et al.
2006a used GRA while Mandal and Breaker 2004 used the V. vulnificus adenine
riboswitch (AR) as their test system. These two riboswitches are virtually iden-
tical with respect to their their overall fold and their binding pocket (Fig. 3.1).
The overall overlay of GRA and AR has an RMSD of only 1.45 A˚ (based on all
atoms) and all binding site residues are conserved and in a similar conformation.
The key binding site nucleotides (A21, U22, U47, U51, A52, U74 & U75) over-
layed within 0.24 A˚ based on all residue atoms. Therefore it was assumed that
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Figure 3.1: Comparison of the B. subtilis xpt-pbuX guanine riboswitch C74U
mutant (GRA) and the V. vulnificus adenine riboswitch (AR) A: Superposition
of GRA (amber/green) and AR (blue). The overall fold is virtually identical
with an RMSD of 1.45 A˚. B: Comparison of the binding sites from both crystal
structures with the AR with green carbon atoms and a green water molecule,
GRA with blue carbon atoms with a red water molecule. The solvent accessible
surface of the AR binding site is displayed in blue. The position of all bases in
contact with the ligand is conserved.
binding data was transferable between both riboswitches.
From the compounds included in this test set (Tab. 3.2), three were cocrys-
tallised with a riboswitch and the coordinates were available from the PDB. These
compounds were 2,6-diaminopurine (Gilbert et al. 2006b; PDB-file 2b57), 2,4,6-
triaminopyrimidine (Gilbert et al. 2006a; PDB-file 2g9c) and adenine (Serganov
et al. 2004; PDB-file 1y26). The structures for 2,6-diaminopurine and 2,4,6-
triaminopyrimidine were in complex with GRA while the structure for adenine
was in complex with AR.
For docking, the structure of the 2,4,6-triamino-pyrimidine in complex with GRA
was selected, since at that time, this was the highest resolution crystal structure
available with a resolution of 1.7 A˚ (Gilbert et al., 2006a).
In order to define the binding site for docking, DOCK 3.5.54 requires a set of
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dummy atoms, sometimes also referred to as ”spheres”. During docking, ring
systems of the compound are used as anchor points and ring atoms are placed
in the vicinity of the docking spheres. The compound-target complexes resulting
from this procedure are then scored (Shoichet et al., 1992). Accordingly, the
sphere set is vital to successful docking. Therefore a systematic protocol for the
generation of the sphere set was developed (Chapter 2.1.2). The binding modes of
the cocrystallised compounds and the separation of scores for the known binders
and non-binders in a score-ranked table were used to assess the performance
of the docking procedure. In the initial docking runs no water molecules were
present in the receptor. With the so prepared receptor the known ligands scored
better on average than the known non-binders. Also the binding modes of 2,6-
diaminopurine and 2,4,6-triamino-pyrimidine were predicted correctly. However,
for adenine an incorrect binding mode was predicted. In the crystallographically
observed binding mode the adenine ligand forms a Watson-Crick base pair with
U74, the N6-amino group pointing in the gap between U22 and U74 (Fig. 3.1 B;
Serganov et al. 2004). The predicted binding mode was oriented differently, so
that the Watson-Crick edges of U74 and the adenine ligand were still facing each
other but the N6-amino group now pointed in the gap between U51 and U74 and
the Hoogsteen edge instead of the sugar edge of the adenine ligand now faced
U51.
The importance of water molecule 364
Close analysis of the available crystal structures led to the hypothesis, that the
water molecule 364 located between U74 and U22 (Fig. 3.1 B) is important for
the orientation of adenine in the binding pocket. A water molecule is located
in this position in all three published cocrystal structures available at that time.
In the adenine bound structure (1y26) this water is part of the hydration sphere
of magnesium ion 125, which is absent in the structure used for docking since
no magnesium was present in the crystallization conditions. However, adenine is
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the only ligand for which this was expected to influence the ligand orientation.
Both 2-6-diaminopurine (compound 1) and 2,4,6-triamino-pyrimidine(compound
5) contain several amino-groups occupying both possible locations for the adenine
N6-amino group, while adenine only contains one amino-group. Therefore water
molecule 364 was included into the receptor and kept present in the docking run.
The effect of the inclusion of the water molecule was threefold (Tab 3.2): Firstly,
adenine was predicted with the correct binding mode and secondly the separation
between binders and non-binders in the score-ranked list of docked compounds
improved. Thirdly, N6-methyladenine (compound 5), a known binder, now scored
worse and the predicted binding mode did not agree with the expected binding
mode. This was no surprise since the N6-methyl group was expected to occupy
the same location as water molecule 364.
To probe the binding mode prediction of the docking approach for a ligand with-
out a known crystal structure the GRA structure complexed with 2-aminopurine
(compound 3) was determined. To further investigate the effect of water molecule
364, the crystal structures of GRA in complex with N6-methyladenine (compound
15) was determined (Tab. 3.1). Crystallization of the GRA in complex with N-
methyladenine was carried out by Colin M. Hammond, a rotation student in the
lab, under supervision of the author. The expected binding mode and the docking
results for compound 15 with and without the water molecule were compared to
these crystal structures. The overall fold of GRA in complex with compound 3
was virtually identical to that of the riboswitch bound to compound 5 which was
used for docking (Fig. 3.2 A). The overall RMSD between the GRA structures
complexed with compounds 3 and 5 based on all atoms was 0.16 A˚. Compound
3 bound to the riboswitch as predicted by the docking algorithm. The purine
ring of the 2-aminopurine was in the same orientation as found in the case of the
adenine complex. The 2-aminogroup pointed into the gap between C74 and U51
(Fig. 3.2 B). It is noteworthy that the water molecule was still observed in the
crystal structure (Fig. 3.2) even though there is no amino-group of the ligand in
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Figure 3.2: Crystal structure of 2-aminopurine bound to GRA at 1.8 A˚. A: su-
perposition of 2-aminopurine bound structure (blue) with the structure which
was used for docking (green). The overall fold is very well conserved and can be
regarded as identical within margin of error (RMSD 0.16 A˚ based on all atoms).
B: binding mode of 2-aminopurine in the binding pocket. The riboswitch bind-
ing pocket is displayed in green carbon atoms, and the 2-aminopurine in amber
carbon atoms. The green mesh represents the Fo − Fc electron density at 3.5 σ
calculated without the ligand and water molecule 101 present. The ligand bind-
ing mode can be assigned unambiguously from these data. In red water molecule
W101 is shown, which is found in a location very similar to W364 in the structure
used for docking.
close range to form a hydrogen bond with. The water molecule 101 only formed
a hydrogen bond with the O2’ hydroxyl group of U22. In case of the co-crystal
structure with N6-methyladenine the overall fold and the binding pocket were
conserved as well. As expected, the orientation of the purine ring in the binding
pocket was the same as for the adenine ligand (Fig. 3.3). The N6-methyl group
displaced the water molecule .
The protonation state of 8-azaadenine
The high score for 8-azaadenine (compound 6) was not attributable to an irrele-
vant binding site conformation. However, it was hypothesized that a negatively
55
Figure 3.3: Crystallographically determined binding mode of N6-methyladenine
(amber carbon atoms) in complex with GRA (green carbon atoms). The green
mesh shows the Fo − Fc electron density map contoured at 3σ, calculated by
omitting the ligand from the final model. The water molecule present in the
other crystal structures is displaced by the N6-methyl group of the ligand.
charged deprotonated species might be dominant under the experimental condi-
tions where the binding experiments were carried out. The pKa of the hydrogen
atom bearing N7 was calculated to be 7.6. Accordingly the compound would
be predominantly deprotonated under assay conditions (pH 8.3). The negatively
charged, deprotonated species when tested by docking received a score of 15.54 kJ
mol
which would result in rank 22 for this compound.
Correcting for the 8-azaadenine protonation state and using the docking score of
N6-methyladenine without the water present would result in a perfect separation
of ligands and decoys in the test set.
3.2.2 Screening of a large compound library and predic-
tion of novel ligands
In order to further explore the ability of the chosen approach for RNA-ligand
docking, a virtual screening library was compiled, docked into the receptor and
top-scoring compounds were selected for experimental evaluation. Our in-house
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virtual compound data-base containing approximately 6.5 million unique com-
pounds was filtered for compounds fulfilling the following criteria:
1. 18 or less non-hydrogen atoms
2. 1 or more hydrogen bond donor and acceptor group
3. total charge between -1 and +2
4. 1 or 2 ring systems
These criteria ensured that the candidate compounds do not violate fundamental
requirements of the binding site.
After docking of these compounds all those that have a positive van der Waals
score were removed from the core-ranked list prior to further analysis. This filter
step removed compounds that were too large to fit the binding pocket or did
not match the binding site shape and ensured that the statistical analysis is not
skewed by obviously non-fitting molecules (Verdonk et al., 2004). This resulted in
a final set of 2592 compounds. To asses the performance of the docking algorithm
the enrichment of the known ligands and decoys from the test among the top-
scoring compounds in the large data set was displayed in a ROC-plot (receiver
operating characteristic, Fig. 3.4).
The enrichment for the ligands is very strong, which is reflected in an area under
curve (AUC) of 0.98. With a theoretical maximum of 1 and a value of 0.5 for
a random distribution of the ligands within the ranked list this corresponds to
a near-perfect performance. The decoys were enriched among the top scoring
compounds as well. The AUC for the decoy set was 0.75, which is still well above
random distribution.
3.2.3 Experimental validation of the screening results
Encouraged by the above mentioned results that validate the in silico approach,
five compounds of unknown binding characteristics from the top-ranking com-
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Figure 3.4: ROC plot of docking results for known ligands and decoys mixed
into in a large set of compounds with unknown binding properties. The sensi-
tivity (fraction of known compounds) was plotted against 1-specificity (fraction
of unassigned compounds in data set). An area under curve (AUC) of 0.98 for
the known ligands (solid line) and 0.75 for the decoys (dotted line) was obtained.
For comparison, a random prediction (dashed line) would yield an AUC of 0.5.
pounds of the virtual screening set were selected for experimental characteriza-
tion after close inspection of their predicted binding mode (Tab. 3.3). From
these five compounds 25, 26 and 27 closely resembled known binders while 24
and 28 were based on molecular scaffolds not previously known from ligands of
this riboswitch.
In order to confirm the binding of the selected compounds to the riboswitch, a
fluorescence competition assay based on 2-aminopurine binding was used. Upon
riboswitch binding the stacking of the 2-aminopurine ligand leads to a drop in
quantum yield for the 2-aminopurine fluorescence (Mulhbacher and Lafontaine,
2007). The ligand to be tested was then titrated into a cuvette containing 2-
aminopurine and the riboswitch and binding was observed as an increase of flu-
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Figure 3.5: Plot of fraction of free 2-aminopurine against the concentration of
compound 27. Data were fitted to a one binding site model with two equilibria.
Data from three titrations are shown together with the resulting fit (solid line).
orescence resulting from the displacement of 2-aminopurine by the tested ligand
in the riboswitch binding pocket. Representative data are shown in Fig. 3.5
using the data obtained for compound 27 as displacement ligand. From the five
selected compounds all except compound 25 were confirmed to bind to GRA.
Interestingly, compound 25 is based on the triazine scaffold (Tab 3.3) which is
also present in compounds 2 (Tab 3.2), 26 and 27 (Tab 3.3).
The determined affinities for the four binding compounds ranged from 80 µM to
650 µM which corresponds to approximately one-thousandfold weaker binding
than the natural ligand adenine. The affinities for the compounds based on
scaffolds not previously observed in ligands for this riboswitch (compounds 24
and 28) are considerably weaker ( 370 µM and 650 µM respectively).
For the four confirmed ligands cocrystallisation in complex with the riboswitch
was attempted and a crystal structure was obtained for three of these four ligands.
The resolutions of the obtained crystal structures ranged from 1.5 to 1.7 A˚ (Tab.
3.1). For compound 28 no crystal structure could be determined. Small crystals
could be grown with this ligand but no crystals of sufficient size for data collection
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were obtained. The limiting factor seemed to be the solubility of the ligand in the
crystallization buffer which limited the maximum concentration of ligand in the
crystallization conditions. This results in combination with the weak affinity of
the ligand for the riboswitch results in a relatively low fraction of the RNA being
bound to the ligand within the crystallization drop. However, the small crystals
observed are a further indication that the compound is a true ligand since until
now no ligand-free structure of this riboswitch is known and crystals can only be
obtained in presence of a ligand.
The overall fold and the binding pocket conformation of the riboswitch cocrys-
tallised with compounds 26 is virtually identical compared with the triaminopy-
rimidine bound structure (RMSD of 0.16 A˚ based on all atoms) which was used
for docking. The ligand orientation could not be unambiguously determined from
the observed density alone, due to ligand symmetry (Fig. 3.6). Therefore, the
position of the water molecule corresponding to water molecule 364 in the struc-
ture complexed with compound 5 was taken into account. This water was shifted
away from the ligand by 0.75 A˚, which was indicative of the methyl group point-
ing in this direction. The ligand forms hydrogen bonds with the Watson Crick
edges of both U51 and U74.
Additionally a water molecule was now located in the complex interacting with
both a ring-nitrogen of the ligand and the 2’-hydroxyl group of U22. No corre-
sponding water molecule was observed in the structure complexed with compound
5. The binding mode of compound 26 was different from the predicted binding
mode by the docking algorithm, which had the methyl group facing the O4 of
U51. However when docking was performed with the shifted water molecule the
correct binding mode was predicted with an RMSD of predicted to observed
binding mode of 0.29 A˚.
The crystal structure of compound 27 bound to GRA was somewhat surprising.
Again, fold and conformation of the binding pocket were conserved between this
structure and the structure used for docking. Compound 27 however, adopted
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Figure 3.6: Crystallographically determined binding mode of compound 26 (am-
ber carbon atoms) to GRA(green carbon atoms). The green mesh shows the
Fo−Fc electron density map contoured at 3 σ, calculated by omitting the ligand
from the final structure. The water molecule W2013 at the opening of the bind-
ing site of this structure is shown in red, it is displaced by 0.75 A˚ compared to
W364 from the structure used for docking (shown in green). An additional water
molecule (W2216) is found in the binding pocket which hydrogen bonds to the
ring nitrogen and one of the exocyclic amino groups of the ligand and the O2’
hydroxyl group of U22.
two binding modes in the GRA binding site (Fig. 3.7). In each of these orien-
tations the ring moiety was located in the center of the binding pocket with the
plane being identical to that of compound 5 (Tab. 3.2). Also one of the two exo-
cyclic amino groups pointed into the cleft between U74 and U51 in both cases.
The other amino group pointed towards the O4 of U51 in one conformation and
towards the O4 of U74 in the other conformation. The ratio of the occupancies
for these binding modes was estimated to 70%:30% (amino group towards O4 of
U51 and U74 respctively) based on crystallographic B-factors. This corresponded
to a difference in binding energy of ∆G ≈ 2 kJ
mol
as followed from the Boltzmann
distribution.
Initially only the second binding mode was predicted by the docking algorithm
with an RMSD of 0.23 A˚. The protocol only reported the single binding mode
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Figure 3.7: Crystallographically determined binding mode of compound 27 (am-
ber carbon atoms) to GRA (green carbon atoms). The green mesh shows the
Fo−Fc electron density map contoured at 2.5σ, calculated by omitting the ligand
from the final model. A water molecule (W2149) is found in a similar location as
W2216 in the 26-GRA complex. The ligand adopts two distinct binding modes.
which is scored best, but when compound 27 was docked into the GRA bind-
ing site while allowing multiple binding modes, the first binding mode was also
predicted with a similar docking score differing only by 1.5 kJ
mol
.
The crystal structure of compound 24 with the riboswitch again showed con-
servation of the overall fold and the binding pocket conformation. The binding
mode of the ligand could be assigned without any ambiguity due to the lack of
symmetry within the ligand and the well defined electron density for the ligand
in this 1.5 A˚ structure (Fig. 3.8). The ligand hydrogen bonded with the Watson-
Crick edges of U51 and U74, the 2’-hydroxyl of U22 and water molecule W2329
which was located in an equivalent position to water molecule 364 of the structure
complexed with compound 5 used for docking. The binding mode observed in
the crystal structure agreed with the binding mode predicted by docking with an
RMSD of 0.21 A˚ which was within experimental error.
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Figure 3.8: Crystallographically determined binding mode of compound 24 (am-
ber carbon atoms) to GRA (green carbon atoms). The green mesh shows the
Fo − Fc electron density map contoured at 2.5 σ, calculated by omitting the lig-
and from the final model. The binding mode of the ligand can be unambiguously
assigned from these data. Water molecule W2329 is found in a similar position
as W364 in the structure used for docking.
When overlaying the binding mode of compound 5 with compound 24 (Fig.
3.9), it became apparent that the molecular interaction pattern for both ligands
is very similar. The guanidino-like moiety including the extra cyclic amino group
pointing into the cleft between U51 and U74 was present in both ligands. Also
both ligands had an amino group interacting with the O4 of U51, which added
up to three hydrogen bonds between U51 and each ligand. The interaction of
the ligands with U74 is different. While compound 5 formed three hydrogen
bonds with U74, compound 24 only formed 2 hydrogen bonds with this base.
But compound 24 formed an extra hydrogen bond to the 2’-hydroxyl group of
U22 which had no corresponding interaction in the binding mode for compound
5.
63
3.3 Discussion
3.3.1 Setup of DOCK 3.5.54 for RNA-ligand docking
Docking algorithms have been applied to proteins for a long time now and drug
discovery has benefited from this technique (Ripphausen et al., 2010). However,
RNA has remained mostly unexplored as a target, even though various RNAs are
validated drug targets (Fulle and Gohlke, 2010). Studies reporting predictions
of new binders which are subsequently tested by structural and biochemical as-
says are lacking. However, these studies are of great importance when probing
the strengths and weaknesses of a docking protocol (Kolb et al., 2009). Partly
this dearth of studies is due to the polyanionic nature of RNA polymers which
poses a more complex problem to docking than proteins which are not system-
atically charged. Even though individual amino acids in a protein can carry a
charge, the peptide backbone is electroneutral and both positively and negatively
charged side chains are found in proteins. In contrast each nucleotide in an RNA
molecule carries a negative charge associated with the under physiological con-
ditions deprotonated phosphate group. To fulfill the fundamental requirement
of electro neutrality in solution this is balanced by counter ions (Draper, 2004,
2008). These can be either bound in specific binding sites or act as diffuse counter
ions which are close to the phosphate backbone but not localized to a specific
position. In essence the concept of a diffuse counter ion is equivalent to a slightly
elevated concentration of positively charged ions in the region around the neg-
atively charged backbone where the ions are otherwise virtually unrestrained in
mobility. Most docking algorithms require a precise location for each atom to
be considered in docking, which poses a challenge to specify the RNA target for
docking since diffuse counter ions are not easily parameterized in such a setup.
If the effects of counter ions are not included into the docking setup the result-
ing electrostatic potential is modeled incorrectly and docking results would be
strongly biased towards positively charged compounds.
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The approach for the results described above was to artificially elevate the par-
tial charges of the phosphate oxygens bearing the negative charge to maintain
overall neutrality. This emulates the effect of diffuse counter ions, whose charge
is shielding the charged groups on the RNA backbone so it contributes less to
the electrostatic interaction with the ligand. This approach has been used in
earlier attempts of RNA-ligand docking (Detering and Varani, 2004; Moitessier
et al., 2006). Apart from the treatment of this electrostatic asymmetry, the scor-
ing function is another crucial factor in docking. The scoring function of DOCK
3.5.54 used here is based on three distinct terms:
1. electrostatic energy
2. van der Waals energy
3. desolvation energy
The reasons that led to the choice of this scoring function are as follows: Firstly,
it is physics based and requires only few parameters specific for RNA. The gen-
eration of lookup files for partial charges and atom types for the RNA-atoms
were sufficient for application of the scoring function. Atom types were easily
assigned manually and the partial charges taken from the AMBER force field,
which has been tested for RNA molecules in the past (Deng and Cieplak, 2010).
Secondly, with the score as the sum of three distinct terms each of which has
a physical meaning, modification or balancing of the scoring function is possi-
ble. The scoring function of DOCK 3.5.54 was developed and tested for proteins.
In principle, the physics based scoring function should work outside the protein
setting equally well, since it does not contain any protein specific adaptations.
Because RNA-ligand interactions are known to be dominated by polar contacts
(Hermann, 2000), it was expected that the scoring function would require some
scaling of the individual terms to account for the RNA situation. Surprisingly,
no modifications were necessary to achieve discrimination between ligands and
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decoys in the test set (Tab. 3.2). Given the dominance of charged interactions
in RNA-ligand complexes compared to protein-ligand complexes, it is actually
somewhat surprising that the same balance of terms as in protein ligand was ob-
served to perform at a comparable level. However, from a fundamental view the
same balance of terms should be applicable in any situation for a physics-based
scoring function like the one used. The dominance of electrostatic interactions
should simply be reflected in the average magnitude of partial charges. In that
respect the docking results confirm the validity of the used scoring function.
The GRA was chosen as a model system because the binding pocket resembles
model binding sites used in protein ligand docking for validation of docking pro-
tocols (Wei et al., 2002; Brenk et al., 2006). The GRA binding site is small
and buried from bulk solvent like the mentioned protein model binding sites and
the known ligands are small and nearly rigid. These characteristics helped ra-
tionalize why certain predictions contradicted the experimental evidence. It was
then possible to adjust the parameters of the docking to achieve agreement be-
tween prediction and experiment. This is discussed below in the context of the
retrospective docking results.
3.3.2 Retrospective results
The observed separation of known ligands and decoys in the test set was nearly
perfect. This is remarkable, especially since the decoys in the test set were very
similar to the ligands (Tab. 3.2). All compounds in the test set were based
on either modified purine or pyrimide scaffolds. All decoys were planar and
able to form at least some of the interactions formed by known similar ligands.
This indicates a sensitivity of the docking algorithm for minor changes that are
experimentally known to prohibit binding.
For an ideal scoring function the docking score and the binding energy (related
to the binding affinity) should be correlated strongly. This correlation is weak
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for the known ligands of the purine riboswitch (Tab. 3.2). Considering the many
approximations and that only three factors of binding energy are accounted for,
this is not overly surprising. The lack of this correlation is also common for
protein ligand docking (Kim and Skolnick, 2008) and there is no reason why
RNA-ligand docking should not suffer from this phenomenon.
The separation of the ligands and decoys is not perfect (Tab. 3.2) and deserves
a more detailed discussion. Compound 15 was initially assigned an unfavor-
able score when docking into the GRA binding site with the water molecule 364
present. From the crystal structure obtained this could easily be rationalized
and the obtained score for docking without the water molecule present was much
more favorable.
The treatment of water molecules which hampered the prediction of the correct
binding mode for compound 15 and also proved essential for correct prediction
of the binding mode for compound 4, is known to pose a serious challenge in
molecular docking (de Beer et al., 2010). It is somewhat unsurprising that this
problem was encountered since the effect of ion and water association with RNA
molecules has been found to be of great importance for ligand binding (Fulle and
Gohlke, 2010).
For the best scoring decoy, compound 6, no such incompatibility of the binding
site could be identified. Instead, the protonation state was not accounted for
correctly, which led to incorrect predictions. This problem is well known for
protein-ligand docking and is described in the literature (ten Brink and Exner,
2009). The conclusion to be drawn from this is that the rule-based generation of
relevant protonation states could be improved. Reliable computational protocols
for the prediction of protonation states and tautomeric states of small ligands are
still under development and are not fully mature yet (Greenwood et al., 2010).
Wherever possible experimental data on protonation states and tautomeric states
should be included for the preparation of screening libraries.
For the assembly of the screening set of compounds the in-house database of
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commercially available compounds was filtered for suitable compounds. The filter
was designed to ensure that the compounds in the data set were chemically diverse
while resembling the known binders in very fundamental properties. The careful
selection of screening compounds and the removal of compounds with a positive
van der Waals score after docking avoided the phenomenon of overenrichment
(Verdonk et al., 2004). In case of over-enrichment the screening set includes a
large number of compounds which cannot bind the target and which could be
excluded by much simpler methods than docking. Following is a brief discussion
of the individual filter categories used to assemble the screening set.
The limitation to a maximum of 18 non-hydrogen atoms ensures molecules do
not exceed the binding site size. This is only a very rough estimate, and by no
means ensures that all molecules fit into the binding site, since molecule shape
is not taken into account. But it is expected that no molecules of more than 18
non-hydrogen atoms fit into the binding pocket in the conformation present in
the crystal structure used for docking. The known ligands present in the test set
(Tab. 3.2) did not exceed eleven non-hydrogen atoms.
Since the in vivo ligand adenine is bound in the binding pocket forming multi-
ple hydrogen bonds with acceptor and donor sites on both the ligand and the
riboswitch, it can be inferred that any ligand will at least have one hydrogen
bond donor and acceptor site. Also the lack of interaction partners for too many
functional groups within the binding site will result in very weak affinities. The
near neutrality of the putative ligands is a requirement resulting from the neu-
trality of the binding site. The whole binding site does not have a net charge
and no formal charges can be found on any of the functional groups interacting
with the native ligand adenine. In order to explore the ability of the binding
site to accommodate charged ligands, compounds bearing a single negative or up
to a double positive charge were taken into account. Interestingly, none of the
molecules that were considered for experimental testing was charged. The overall
neutrality of the binding site seems to have selected strongly for neutral ligands.
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The requirement of one or two ring systems was motivated by the observation
that all known ligands for this riboswitch contain a ring system. This ring system
in all known cases is aromatic and the ring is stacked in between nucleo-bases
for all known crystal structures. Therefore, it was concluded that any potential
ligand would have to contain a ring system.
When docking a large set of compounds into the GRA binding site, the known
ligands accumulated in the top part of the score-ranked list (Fig. 3.4). This is
the desired outcome for this experiment. Known binders should have a favorable
score and rank high in a chemically diverse set of compounds where only a small
minority will bind to the riboswitch target. For the decoys an enrichment is
achieved as well. Ideally a set of decoys would not be enriched and an AUC of
0.5 would be obtained in a ROC plot. This would reflect a random distribution
of the decoys in the score-ranked list. The enrichment of the decoy set in this
situation has been attributed to the similarity of the decoys to known ligands.
Most decoys only differ from ligands by a single functional group. In contrast the
screening set in whole is much more chemically diverse, so the decoys used are not
spanning the whole chemical space of the screening library. A slight enrichment
of the decoys in these circumstances is unsurprising and unproblematic as long as
discrimination of ligands and decoys is achieved. Still even though the decoys are
enriched, they span the upper 50% of the score-ranked docking list almost evenly.
In contrast the ligands only span the upper 20% and all but one are found in
the top 2% of the screening set (Fig. 3.4). So, in summary separation of ligands
and decoys is achieved and the performance of the docking protocol is regarded
as satisfactory.
3.3.3 Prospective results
While the ability to reproduce known binding data is encouraging, the real test for
any docking algorithm is whether it can predict novel ligands for a given target.
69
This is the practical purpose of virtual screening after all and the common appli-
cation for docking in the drug discovery context. To test the predictive power of
the docking algorithm used, five compounds from the 25 best-scored compounds
were selected for experimental characterization after manual inspection of the
predicted binding modes. From these five compounds three were closely resem-
bling known ligands and two compounds based on scaffolds not found in known
ligands (Tab. 3.3). Four of the selected five compounds were confirmed to bind
the riboswitch, which is a very encouraging success rate.
The only selected compound, 25, that was found not to bind the riboswitch
closely resembled previously known ligands. Compound 25 is based on the same
scaffold as the triazine ligands and very similar to the pyrimidine ligands. It
differs from compound 2 only in the replacement of one extra cyclic amino group
by a chlorine atom. None of the ligands in the test set contain a chlorine atom
while two of the decoys do. Therefore this was considered a very interesting test
case. There are two possible reasons for the observed lack of binding: the pos-
sible locations for the chlorine atom would be in close proximity to oxo-groups
from surrounding bases, while the angular requirements for a C-Cl-O interaction
(Bissantz et al., 2010) are not satisfied. The second factor is the inductive effect
of the chlorine which is expected to act on the basicity of the ring nitrogens and
thereby is expected to render them less basic. This results in weaker hydrogen
bonds leading to a loss in binding affinity. The scoring function used here does
not have the capability to include these effects in the predictions. While it would
be beneficial to extend the scoring function to include angular effects, it is re-
markable how well the scoring function performs without any terms considering
angular dependencies. The inductive effect would have to be treated by a mod-
ified approach to ligand preparation, namely a more sophisticated protocol for
the assignment of partial charges to the ligand atoms.
Compound 27 differs from compound 2 only by the absence of a single amino
group. The binding of this compound was expected, the observed fourfold drop
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in binding affinity and the associated decrease in binding energy is very well ex-
plained by absence of the interactions from the missing amino group. The crystal
structure of the complex of the riboswitch with compound 27 revealed a double
binding mode. One of the observed binding conformations was the one predicted
by the docking algorithm. The other binding mode was initially not predicted.
This was, however, due to the setup of the docking algorithm, which only predicts
one binding mode per compound in the screening set. Since upon consideration
of more than one binding mode with favorable score both binding modes were
predicted, the docking protocol was in principle capable of reproducing the ob-
served double binding mode. The occurrence of multiple binding conformations
with near-optimal characteristics is a well-known phenomenon in docking and
protocols accounting for the associated effects are being developed (Gorelik and
Goldblum, 2008; Stjernschantz and Oostenbrink, 2010). Thus, this is another
example of RNA-ligand docking suffering from the same problems already known
from protein-ligand docking.
The binding of compound 26 was not unsurprising given the similarity to com-
pounds 2, 5 (Tab. 3.2) and 27 (Tab. 3.3). It differs from compound 2 only by
the replacement of one amino group by a methyl group. The measured affinity
for compound 26 is very similar to compound 27. Therefore it can be concluded
that the methyl group does not contribute any significant binding energy but is
also not detrimental to binding. Compound 26 has better shape complementarity
to the binding pocket than compound 27, however the water molecule near U22
needs to be shifted in location to make room for the methyl group. The binding
mode was not correctly predicted by the docking algorithm, which is explained
by the fact that the water molecule was kept in the original place during docking.
This presents the third example apart from compound 4 and compound 15 where
the correct binding mode prediction is sensitive to the water molecule used for
docking.
Upon docking with the observed location for the essential water molecule, the
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correct binding mode was predicted. This underpins the confidence in the scoring
function but again points out a limitation of the used docking approach already
observed for the binding of adenine. The location of water molecules and the
prediction of their involvement in binding has proven to be a challenge for docking
for a long time (see above).
Compound 28 was found to bind the riboswitch with the weakest affinity of the
newly discovered ligands. Unfortunately all crystals that could be obtained were
insufficient in size for data collection. Attempts to improve the crystals were
unsuccessful and this was attributed to the solubility limit of the ligand. The
molecular scaffold of compound 28 was not observed previously in GRA ligands.
This ligand is the smallest known to bind this riboswitch and is based on a 1,2,4-
thiadiazole moiety. Additionally, the two heterocyclic nitrogens and the exo-
cyclic amino group closely resemble the guanidino-like moiety found in several
known ligands including compounds 1, 2, 5 and 27. Therefore it would have
been interesting to study the adaptation of the binding pocket to accommodate
this small ligand. The degree of flexibility for this binding pocket is yet to be
determined, even though experimental evidence suggests the ability to adjust to
various requirements for ligand binding (Edwards and Batey, 2009; Gilbert et al.,
2009).
Compound 24 is the only ligand based on a novel scaffold for which a co-crystal
structure could be determined. The binding affinity of 350 µM is rather weak
but binding still could be confirmed. The binding mode was predicted correctly
which boosts the confidence in the selected docking protocol. When comparing
the binding mode of compound 24 to the riboswitch with the binding mode of
the original ligand from the crystal structure a great similarity in the interaction
pattern becomes apparent (Fig. 3.9). This is somewhat surprising since the chem-
ical structure of the two compounds differs greatly. While compound 24 is based
on two fused five-membered rings the original ligand from the crystal structure
is based on a pyrimidine scaffold. Both ligands interact with the Watson-Crick
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Figure 3.9: Comparison of the binding modes of compound 5 (RNA and ligand in
blue carbon atoms, water molecule in blue, hydrogen bonds in red) and compound
24 (RNA and ligands in green carbon atoms, water molecule in green, hydrogen
bonds in black). Overall the ligand-receptor interactions are very similar for both
ligands. The hydrogen bonds between compound 5 and U51 are parallel and have
near optimal geometry while for compound 24 the hydrogen bonds to U51 are
not parallel and have less optimal geometry. Also compound 5 has an amino
group forming a hydrogen bond with the U74 O4 while compound 24 does not
form a hydrogen bond with this group.
edges of U51 and U74 and the water molecule 364 in case of triaminopyrimidine
or water molecule 2013 in case of compound 24, respectively. U51 forms three
hydrogen bonds with both ligands but in case of compound 24 these are slightly
deviating from the ideal angle of a hydrogen bond (Fig. 3.9). The distance of
the two exo-cyclic amino groups is greater than required for optimal hydrogen
bonding (Fig. 3.9). U74 forms three hydrogen bonds with triaminopyrimidine
while only two are formed with compound 24. This lack of one hydrogen bond
and the less ideal hydrogen bonds to U51 are likely the reasons for the reduced
affinity of compound 24 compared to compound 5. Both ligands interact with
the water molecule close to U22. Interestingly, the location of the ligand atom
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forming the hydrogen bond varies between the ligands while the water molecule is
in a very similar location in both cases. Compound 24 forms one extra hydrogen
bond to the riboswitch compared to compound 5. This hydrogen bond is formed
between the 2’-hydroxyl of U22 and the N2 of the ligand.
Overall, the prediction of ligand binding modes proved to be accurate provided
the relevant binding site conformation is used for docking. Compound 24 was
predicted correctly right away and the observed binding modes for compounds 26
and 27 were predicted correctly after providing the correct location of the crucial
water molecule and allowing for multiple binding modes. In future development
these issues will need to be addressed to ensure accurate predictions in a wider
set of circumstances. The ability to correctly predict the binding modes of novel
ligands is the most important feature of any docking protocol. In a drug discovery
context virtual screening by molecular docking is used to identify novel ligands.
Even successful prediction of ligand binding, but with an incorrect binding mode,
is of limited value. The agreement of predicted and observed binding mode is an
indication that the prediction is real and not just a coincidence. It has previously
been observed that even though binding is correctly predicted for a compound
to a given target, the observed binding mode significantly deviates from the
predicted one (Mpamhanga et al., 2009). In such cases the docking still needs to
be considered a failure, since the prediction was based on incorrect calculations.
3.3.4 Conclusions
In the reported approach on RNA-ligand docking known experimental data was
successfully reproduced and new ligands were predicted successfully. The repro-
duction of known binding data was a first success which was underpinned by
the successful identification of several causes for mispredictions. The rational-
ization of the mispredictions and the successful predictions of the real binding
modes upon correction point to a good choice of the GRA as a model system.
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Identification of novel ligands proved the usefulness of the protocol in a drug dis-
covery setting. However, not unexpectedly several problems with RNA-ligands
were identified despite of the overall success. Surprisingly, none of these problems
were RNA-specific but the identified problems are well known from protein-ligand
docking. The treatment of water molecules has been a substantial challenge and
is still a current topic for research. Also the treatment of tautomeric states and
protonation states has been previously known to be an issue (ten Brink and
Exner, 2009; Greenwood et al., 2010). Theoretically, the energy of all possible
states would have to be determined and each binding score would have to be
adjusted by the energy of that state. In practice the tautomers and protonation
states relevant to docking are often determined by a rule-based approach as in
this study.
Finally, it is important to note that the above discussion is referring to the binding
properties of the isolated aptamer domain only. Activity on the full riboswitch
including the expression platform in vitro and in vivo of these compounds is
yet to be tested. Especially for riboswitches under kinetic control, the binding
affinity could deviate significantly from the concentration required to alter gene
expression.
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Table 3.2: Test set of experimentally confirmed ligands and decoys taken from the
literature. All KD values quoted are from the respective publications (Mandal
and Breaker, 2004; Gilbert et al., 2006a).
Compound No. Structure Rank Score [ kJ
mol
] RMSD [A˚] KD[µM]
1 1 -34.18 0.24 0.01
2 2 -33.97 NA 20
3 3 -32 NA 0.3
4 4 -31.85 0.34 0.3
5 5 -31.81 0.13 20
6 6 -30.44 NA NA
7 7 -29.90 NA 30
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Table 3.2: Test set of experimentally confirmed ligands and decoys taken from the
literature. All KD values quoted are from the respective publications (Mandal
and Breaker, 2004; Gilbert et al., 2006a) (continued).
Compound No. Structure Rank Score [ kJ
mol
] RMSD [A˚] KD[µM]
8 8 -26.71 NA 20
9 9 -25.11 NA NA
10 10 -23.24 NA NA
11 11 -21.36 NA NA
12 12 -20.03 NA NA
13 13 -18.99 NA NA
14 14 -18.33 NA NA
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Table 3.2: Test set of experimentally confirmed ligands and decoys taken from the
literature. All KD values quoted are from the respective publications (Mandal
and Breaker, 2004; Gilbert et al., 2006a) (continued).
Compound No. Structure Rank Score [ kJ
mol
] RMSD [A˚] KD[µM]
15 15 -17.49 NA 100
16 16 -15.97 NA NA
17 17 -14.48 NA NA
18 18 -14.17 NA NA
19 19 -11.97 NA NA
20 20 -9.93 NA NA
21 21 -8.50 NA NA
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Table 3.2: Test set of experimentally confirmed ligands and decoys taken from the
literature. All KD values quoted are from the respective publications (Mandal
and Breaker, 2004; Gilbert et al., 2006a) (continued).
Compound No. Structure Rank Score [ kJ
mol
] RMSD [A˚] KD[µM]
22 22 -7.01 NA NA
23 23 15.92 NA NA
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Table 3.3: Compounds selected and subsequently tested for binding and subjected
to crystallography.
Compound No. Structure Rank RMSD [A˚] KD[µM]
24 3 0.21 340± 40
25 7 NA NA
26 11 0.29 110± 30
27 14 0.65/0.23 80± 20
28 33 NA 650± 180
RMSD in A˚ between docking prediction and binding mode from the crystal struc-
ture
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Chapter 4
Virtual screening for the T.
tengcongensis SAM-I riboswitch
4.1 Overview
To apply RNA-ligand docking in a drug discovery scenario, virtual screening
for novel ligands for the SAM-I riboswitch was performed. First, the docking
protocol was validated for this target by reproduction of crystallographically de-
termined binding modes. Then promising potential binders were identified from
the docking results of a large set of compounds. Compounds were then purchased
and tested for binding. One novel binder could be identified among the tested
ones.
4.2 Results
4.2.1 The SAM binding site
The SAM-I riboswitch was selected for this virtual screening study since it was im-
plicated to be a potential drug target (Blount and Breaker, 2006). The sequence
of the T. tengcongensis SAM-I riboswitch is similar to the SAM-I riboswitches in
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pathogenic bacteria. Also the binding site did offer challenges beyond the model
binding site of the GRA (Daldrop et al., 2011). The SAM-I binding pocket is
considerably larger, binds to flexible ligands and is partly solvent accessible (Fig.
1.8; Montange and Batey 2006). Additionally, binding data and crystal struc-
tures for the SAM-I riboswitch and several ligands were available to validate the
initial docking setup. This also implied that the SAM-I riboswitch would be
amenable to cocrystallization with potential novel ligands.
4.2.2 Docking of SAM analogues
To validate the docking setup, ligands for which the binding modes are known are
usually redocked into the receptor binding site (Hartshorn et al., 2007). In case
of this riboswitch docking of the natural SAM ligand (Fig. 4.1) into the SAM-I
riboswitch binding pocket was not possible. The protocol for generation of a dock-
able database does not allow for a positively charged trivalent sulfur atom to be
present in the ligand because the force fields used for ligand preparation contain
no parameters for this atom. The conformational flexibility of the compounds to
be docked was taken into account by docking an ensemble of precalculated low-
energy conformers, which were generated and scored with the MMFF94 force
field (Halgren, 1996). This force field does not contain any parameters for the
sulfur atom contained in the SAM-ligand. However, analogues of SAM compati-
ble with the docking protocol had been crystallized in complex with the SAM-I
riboswitch (Montange et al., 2010). These were used to validate the receptor
setup and the docking protocol. These analogues are S-adenosylhomocystein
(SAH) and sinefungin (SFG), also known as S-adenosylornithine (Fig. 4.1). The
binding modes of the SAM analogues SAH and SFG are almost identical to the
binding mode of SAM (Fig. 4.2) which is reflected in an RMSD of 0.5 A˚ (based on
all non-hydrogen atoms present in both structures) between SAM and SAH, and
an RMSD of 0.45 A˚ between SAM and SFG. SAH differs from SAM only by the
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Figure 4.1: Chemical structure of SAM and SAM analogues used to validate the
docking setup by redocking into the SAM-I binding site.
absence of the methyl group attached to the sulfur atom. This relatively small
change has one important consequence: the sulfur atom now is only connected
to two neighboring atoms and is uncharged. The affinity of SAH for the SAM-I
riboswitch was reported as approximately 100 fold weaker than the affinity for
SAM (Montange et al., 2010; Winkler et al., 2003). In SFG the SAM-sulfur is
replaced by a carbon atom and the methyl group is replaced by an amino group
(Fig. 4.1). The binding constant was reported to be 180-fold weaker than for
SAM (Montange et al., 2010). To these two analogues S-adenosylcystein (SAC)
was added for which no structural data was available. However, for the B. subtilis
yitJ SAM-I riboswitch SAC was reported to bind with 30 µM affinity (Winkler
et al., 2003). Due to its highly similar chemical structure SAC was assumed to
exhibit a binding mode closely resembling that of SAH.
Docking of these ligands was performed using the same protocol as described for
the GRA (Chapter 3). The sphere set to define the binding pocket was limited
to the area usually occupied by the SAM-adenine. The docking results for SAC,
SAH and SFG vary in their agreement with the known or expected binding modes.
Docking of SFG did not reproduce the crystallographically observed binding mode
(Montange et al., 2010). Not even substructures of the ligand were placed cor-
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Figure 4.2: Comparison of the binding mode for SAM and SAM-analogues to the
SAM-I riboswitch. A: Wall-eyed stereo view of the superposition of the binding
mode of SAH (amber carbon atoms) and SAM (amber carbon atoms) in the
SAM-I binding site (green carbon atoms) from PDB-file 2gis. B:Wall-eyed stereo
view of the superposition of the binding mode of SFG (amber carbon atoms)
and SAM (amber carbon atoms) in the SAM-I binding site (green carbon atoms)
from PDB-file 2gis.
rectly (not shown). For SAH, the predicted binding mode agreed with the ob-
served one at least with respect to the general location of the adenine part of the
ligand (Fig. 4.3).
For SAC, for which no structural data was available, the predicted binding mode
was very similar to the one expected based on the observed binding mode for
SAH. Particularly the adenosine moieties aligned well with an RMSD of <0.8 A˚.
Considering these results one trend became apparent: The agreement between
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Figure 4.3: Wall-eyed stereo view of the predicted binding mode of SAH (amber
carbon atoms) in the SAM-I riboswitch binding pocket (green carbon atoms).
The experimentally observed binding mode for SAH is shown in cyan carbon
atoms.
experimental data and prediction is best for the SAC which contains the shortest
amino acid moiety and deteriorated with increasing size of the amino acid moiety
of the ligand. As a close inspection of the conformational ensembles generated for
these ligands revealed, this was caused by insufficient conformational sampling.
Two measures were taken to validate the docking setup despite this problem:
1. The ligand conformations for SAH and SFG observed in the crystal struc-
ture of the riboswitch ligand complex were docked into the binding pocket.
2. Adenosine (Fig. 4.1) was docked into the binding pocket.
Docking of the crystallographically observed conformation of SAM-I bound SAH
and SFG resulted in predictions that were almost identical to the known binding
modes (Fig. 4.5). The RMSD between prediction and known binding mode was
0.24 A˚ for the SFG and 0.23 A˚ for the SAH. The docking scores of these confor-
mations were more favorable than the ones obtained in the previous docking.
Next, adenosine was docked into the SAM-I riboswitch. The predicted binding
mode was in agreement with the the adenosine parts of the known ligands (SAM,
SFG and SAH). This is reflected in an RMSD of 0.25A˚ between the predicted
binding mode for adenosine and the SAM-adenosine moiety from the crystal
86
Figure 4.4: Wall-eyed stereo view of the predicted binding mode of SAC (amber
carbon atoms) in the SAM-I riboswitch binding pocket (green carbon atoms).
The experimentally observed binding mode for SAH as a comparison is shown in
cyan carbon atoms. The adenosine parts of the experimentally determined SAH
binding mode agrees well with the SAC binding mode prediction.
structure.
Taken together these results led to the conclusion that the failures in redock-
ing were due to insufficient conformational sampling rather than the inability to
correctly judge the ligand-receptor interactions. For the planned virtual screen-
ing this was not considered to be a relevant problem due to the nature of the
compounds in the screening set (see below).
Figure 4.5: A: Superposition of the predicted binding mode for SAH using only
the conformation observed in the crystal structure (amber carbon atoms) and the
known binding mode( green carbon atoms). B: Superposition of the predicted
binding mode for SFG using only the conformation observed in the crystal struc-
ture (amber carbon atoms) and the known binding mode( green carbon atoms).
87
4.2.3 Assembly of a screening set of compounds
A set of compounds to be docked into the SAM-I binding site was assembled
in order to proceed with the virtual ligand screening. The in-house database of
commercially available chemical compounds contained approximately 6.5 million
unique chemical compounds (Brenk et al., 2008). Compounds were selected from
this database using the following criteria:
• maximum of 26 non-hydrogen atoms
• maximum molecular weight of 500 Da
• minimum of 2 hydrogen bond acceptors and 2 hydrogen bond donors
• one or two ring systems
• net charge between 0 and +2
• maximum of 4 rotatable bonds
• no unwanted groups
The rationale for these criteria are as follows: A maximum of 26 non-hydrogen
atoms and 500 Da molecular weight puts an upper limit on the size of the po-
tential ligands. In drug discovery this is very common practice to ensure drug
likeness (Lipinski, 2001). Next, the minimum of four functional groups capable
of hydrogen bonding ensures that the compounds have the potential for multi-
ple strong interactions with the SAM-I binding site which is required for a high
affinity ligand. The minimum of one ring system is a requirement of the binding
pocket since all known ligands contain an adenine moiety, and the area of the
binding pocket where this moiety binds is prone to be occupied by a ring system.
The requirement for the net charge was derived from the cationic nature of the
natural SAM ligand which bears a net charge of +1. Since neutral ligands like
SAH were reported in the literature (Montange et al., 2010; Lim et al., 2006), a
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margin of ±1 in net charge was tolerated. A maximum of four rotatable bonds
ensured that the conformational space could be sufficiently sampled, avoiding
the complications experienced with the SAM-analogues. Finally, exclusion of
compounds containing functional groups defined as unwanted ensured that the
obtained compounds did not contain structural features which are known to be
problematic in drug discovery (Brenk et al., 2008). In total, ≈ 95, 000 compounds
passed all filters and constituted the screening set.
4.2.4 Analysis of docking results and selection of com-
pounds for experimental characterization
The screening set was docked into the SAM-I riboswitch binding site. For dock-
ing the same sphere set was used that was also used for docking of the SAM
analogues, only covering the area where the adenine moieties of the known lig-
ands are located. A total of ≈ 66000 compounds was successfully placed into
the binding pocket and scored. The score-ranked list of docked compounds was
analyzed to identify candidates for experimental study. To guide the selection of
compounds for experimental testing, the list was further filtered using a pharma-
cophore (Fig. 4.6). The pharmacophore was developed based on a three hydrogen
Figure 4.6: Pharmacophore for filtering of the SAM-I docking results. The crucial
nucleotide U57 is shown in green carbon atoms, the SAM-ligand in cyan carbon
atoms. The pharmacophore is composed of two donor groups (yellow spheres)
and an acceptor functionality (grey sphere).
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bond interaction pattern with U57. Donor functionalities were placed close to
the O2 and O4 of U57 and an acceptor functionality close to the N3 of U57 (Fig.
4.6). The docking results were subsequently filtered requiring two of these three
molecular recognition characteristics to be present. A total of 307 compounds
matched these requirements.
Table 4.1: Compounds selected from the docking results for the SAM-I riboswitch
and subsequently tested for binding.
Compound No. Structure Score Compound No. Structure Score
1466736 -36.58 2071368 -32.16
1672502 -30.90 4051493 -34.03
1820323 -30.33 5155566 -22.44
1946503 -22.82 5669778 -32.93
Finally a set of eight compounds was selected based on visual inspection of the
307 binding mode predictions for experimental testing and ordered from the re-
spective suppliers (Tab. 4.1). The selected compounds differed in molecular
weight ranging from 140 Da for the smallest compound to about 365 Da for the
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Figure 4.7: Binding mode predictions for selected compounds (Tab. 4.1) from
a virtual screening of the SAM-I riboswitch. The key binding site nucleotides
from the riboswitch structure (PDB-file 2gis) are shown in green carbon atoms.
The binding mode predictions are shown in cyan carbon atoms with the pre-
dicted hydrogen bonds between compound and receptor indicated as black dashes.
The SAM-ligand is shown with yellow carbon atoms. A: Prediction for com-
pound 1466736, B: Prediction for compound 1672502, C: Prediction for compound
1820323, D: Prediction for compound 1946503.
largest compound and were based on a variety of molecular scaffolds. The pre-
dicted binding modes for the selected compounds are shown in figures 4.7 and 4.8.
As required by the pharmacophore all compounds form multiple hydrogen bonds
with U57 and a heterocycle occupies the area in which the adenine moiety of the
SAM is bound in its complex structure. From this selection compound 1820323
(Tab. 4.1 and Fig. 4.7) requires a closer inspection. This compound differs from
adenosine (Fig. 4.1) only in two ways, first the nucleobase carries an additional
amino group at the C2 position and second the sugar moiety differs in its stereo
chemistry. In the docking prediction the sugar is an arabinose rather than the
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Figure 4.8: Binding mode predictions for selected compounds (Tab. 4.1) from a
virtual screening of the SAM-I riboswitch. The key binding site nucleotides from
the riboswitch structure (PDB-file 2gis) are shown in green carbon atoms. The
binding mode predictions are shown in cyan carbon atoms with the predicted hy-
drogen bonds between compound and receptor indicated as black dashes. Where
appropriate the SAM-ligand is shown with yellow carbon atoms. A: Prediction
for compound 2071368, B: Prediction for compound 4051493, C: Prediction for
compound 5155566, D: Prediction for compound 5669778.
ribose observed in standard nucleic acids. Unfortunately, the arabinose variant of
this ligand was not available commercially, so the ribose variant of this compound
(also known as 2-aminoadenosine) differing only in the stereo conformation of the
C2’ was bought for experimental testing.
The ribose variant of compound 1820323 was also docked into the SAM-I binding
site and obtaining a score of -26.39 kJ
mol
which is less favorable than the -30.33 kJ
mol
for the arabinose version. The predicted binding mode is shown in figure 4.9.
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Figure 4.9: Wall-eyed stereo view of the predicted binding mode of 2-
aminoadenosine (grey carbon atoms) to the SAM-I riboswitch (green carbon
atoms) with the hydrogen bond interactions highlighted as black dashed lines.
The SAM ligand from the crystal structure is shown in yellow carbon atoms.
4.2.5 Experimental testing of the selected compounds
The selected compounds were then tested for SAM-I binding using ITC (Wise-
man et al., 1989). Since the affinity for these compounds was expected to be very
low, a direct ITC approach was considered inadequate. Therefore, the ITC mea-
surements were carried out as a competition experiment (Zhang and Zhang, 1998;
Turnbull, 2005), where SAM was titrated into a solution of SAM-I riboswitch in
absence and presence of the compound to be tested. In case of the compound
binding the SAM-I riboswitch, the obtained apparent affinity for SAM to the
riboswitch in the presence of that compound would be lowered. For the ITC
experiments compounds had so be solubilised in DMSO at a concentration of
100 mM. Unfortunately only four of the eight compounds selected were soluble
at this concentration and could be tested for binding by ITC. The compounds
tested were:
• Compound 1820323 (Fig. 4.9)
• Compound 4051493 (Fig. 4.8 B)
• Compound 5155566 (Fig. 4.8 C)
• Compound 5669778 (Fig. 4.8 D)
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From the four compounds tested only compound 5669778 was observed to bind to
the SAM-I riboswitch. The titration data recorded in the absence and presence
of compound 5669778 are shown in figure 4.10. The apparent affinity obtained
from the fit of the data was 120 nM in the absence and 740 nM in the presence of
2 mM compound 5669778. The binding affinity for this compound was calculated
to be 380 µM.
Figure 4.10: Isothermal titration calorimetry of SAM binding to the SAM-I ri-
boswitch in competition with compound 5669778. SAM is titrated to a solution
of SAM-I riboswitch in the absence and presence of 2 mM compound 5669778.
Data were then fitted to a two state binding model and the binding constant of
compound 5669778 was calculated from the apparent decrease of SAM affinity in
the presence of compound 5669778. The so calculated binding constant was 380
µM.
In parallel cocrystallisation of the SAM-I riboswitch with each of the eight se-
lected compounds was attempted. Crystals were obtained in the presence of all
compounds except for compounds 1672502 and 1946503. However, crystal struc-
ture analysis revealed that the crystals only contained the apo-structure (Fig.
1.9)
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4.3 Discussion
4.3.1 Docking setup
The SAM-I riboswitch was chosen for this docking study since it was expected
to be a more challenging target than the purine riboswitch. Moreover, the SAM-
I riboswitch was implicated as a potential antibacterial target and was found
multiple times in the genome of bacteria, especially firmicutes. Identification
of novel binders would be a first step in exploitation of this riboswitch as an
antimicrobial target and offer potential applications.
Unfortunately the protocol used to prepare the putative ligands did not allow
for direct docking of the in vivo ligand SAM. The sulfonium group which was
prohibitive for docking is a rare occurrence in libraries for virtual screening. Our
in-house database of commercially available compounds contains only 245 exam-
ples in about 6.5 million compounds. Compounds of this type would usually
be considered undesirable in drug discovery because of their instability. While
in theory the protocol could be adapted to allow this type of compounds the
required effort outweighs the benefit by far.
Docking of the SAM-analogues was hampered by the insufficient sampling of
conformational space for SAH and SFG. The required conformations were absent
in the precalculated ensemble of conformations in the dockable database. The
ability of the protocol to correctly predict the binding mode of SAH and SFG
in principle was demonstrated by redocking of the conformations observed in the
crystal structure. Since these predictions also received more favorable scores than
the predictions from the initial docking run, the problem can be pinpointed to
the generation of a complete ensemble of conformations. Further evidence for
this interpretation stems from the prediction of the binding mode for adenosine.
Adenosine is far less flexible than SAH or SFG and the predicted binding mode
aligns well with the adenosine moieties of SAM, SAH and SFG. This suggests
that RNA-ligand interactions are judged correctly. When docking flexible ligands
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special care should be taken in the future to avoid this problem. It is noteworthy
that the insufficient sampling of conformational space for the SAM-analogues is
in no way a specific problem of RNA-ligand docking (Agrafiotis et al., 2007).
In fact, the problematic part of the protocol is completely independent of the
receptor. Nevertheless a more suitable treatment of highly flexible ligands would
be desirable to solve the problem.
4.3.2 Docking of a large set of compounds
The screening set was assembled by filtering the available commercial compounds
for desirable criteria and finally contained just under 100,000 compounds. After
filtering the obtained docking results with a pharmacophor, 307 unique ligands
remained, which were visually inspected.
The eight compounds selected all were restricted to the area of the binding pocket
usually binding the adenosine part of the SAM-ligand. None of the ligands
spanned the whole area usually occupied by the SAM. This is to a large de-
gree a consequence of the used sphere set, which was restricted to the adenine
area, in combination with the pharmacophore filtering which enforces two hy-
drogen bonds between the compounds and U57. In principle, interactions with
nucleotides outside this area are not selected against, but would be considered
desirable. One way of addressing this issue would be assembly of a second screen-
ing set with relaxed criteria for the compound filter to include compounds which
would be able to interact with these different parts of the binding pocket. Es-
pecially allowing for a maximum of approximately 30 non-hydrogen atoms and
relaxing the restriction of a maximum of two ring systems appear valid modifi-
cations of the filter.
96
4.3.3 Experimental binding data
In the course of this study one novel ligand for the SAM-I riboswitch was dis-
covered. Form the eight compounds selected only four were amenable to ITC
measurements due to issues with solubility. Poor solubility of compounds is a
well known problem in drug discovery (Lipinski, 2001) and there is no indication
that the solubility issues experienced in this study are not within expectations. To
overcome these solubility issues, the following approaches might be used. First,
the ITC assay itself still has some room for improvement, using higher RNA
concentrations would allow for lower compound concentrations by improving the
signal to noise ratio. This would allow detection of smaller differences in ap-
parent SAM affinity, which in turn would allow for a lower concentration of the
competing compound. However, since already 10 nmol of riboswitch RNA per
titration are used, increasing the RNA concentration will make the assay very
expensive and time consuming. To overcome this limitation a newer generation
of ITC instruments, such as the ITC200 instrument (GE Healthcare) could be
used which requires approximately seven-fold less sample.
Second, different solvents could be explored, which might solve the problem by al-
lowing solubilisation of compounds not soluble in DMSO. Third, different binding
assays could be used, not requiring such high ligand concentrations. Currently
no obvious alternative stands out but possible options include NMR-based assays
or an in-line probing assay.
From the compounds tested which did not bind the riboswitch, compound
1820323 (Tab. 4.1) is closely related to adenosine and is structurally related to
the SAM ligand. However the result from the screen was based on an arabinose
sugar, while the only commercially available similar compound which was then
tested was based on a ribose sugar. The compound was purchased and tested
despite the difference in stereo chemistry because of the high structural similarity
to the adenosine substructure in the SAM ligand. Unfortunately no binding
97
data is reported on adenosine but only on AMP, which is negatively charged.
The reported lack of binding for AMP would be expected while adenosine might
still bind with weak affinity. To obtain a more complete picture whether the
SAM-I riboswitch is capable of binding ribosides, adenosine binding needs to be
investigated.
Compound 5155566 (Tab. 4.1) was the smallest of the ligands selected from the
screen. It also received the least favorable score in the set of compounds selected
for experimental characterization. This was however believed to be compensated
by its small size, according to the principle of ligand efficiency (Hopkins et al.,
2004). It would have been interesting to see if and how the binding site adapts
to accommodate for such a small ligand. But since only a small part of the
binding pocket interacts with this ligand, it seems that the predicted interactions
are not sufficient to stabilize the predicted ligand-riboswitch complex. From the
apo-structure it is known that the binding site conformation in the bound and
unbound states differs significantly (Fig. 1.9; Stoddard et al. 2010). The A46
adenine moiety needs to be displaced from the binding pocket to allow binding
of the SAM-adenine moiety. The failure to detect any binding for compound
5155566 could be caused by the conformational plasticity of the binding pocket.
The third compound not displaying any binding was compound 4051493, which
is based on a purine scaffold linked to a piperazine ring. This compound was
predicted to form only four hydrogen bonds with the receptor (Fig. 4.8) and all of
these are formed under participation of the purine-moiety. The piperazine moiety
with its attached terminal groups does not participate in any interactions and the
shape complementarity for this part of the ligand is poor. The combination of
a small number of hydrogen bond interactions being formed and the poor shape
complementarity can explain the lack of observable binding.
But apart from the challenges this project posed, one new ligand was discovered
for this riboswitch. Compound 5669778 (Tab. 4.1) is the first ligand for the SAM-
I riboswitch which is not a close SAM analog. The binding data presented here
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(Fig. 4.10) still leaves some room for improvement and the measurements need to
be repeated to obtain a statistical measurement of accuracy. While being a weak
binder on an absolute scale the compound does exhibit a comparatively strong
ligand efficiency (Hopkins et al., 2004). The 370 µM with 17 non-hydrogen atoms
corresponds to a ligand efficiency of approximately 0.28 kcal
mol·HA . As a comparison
the ligand efficiency of the SAM is 0.33 kcal
mol·HA and 0.24
kcal
mol·HA for SAH. Therefore,
the discovered ligand is not as good as SAM in terms of ligand efficiency but
performs better than the SAM analogues known to bind the riboswitch. The
classic target value for drug discovery 0.3 kcal
mol·HA is just slightly higher than the
value obtained and in a drug discovery scenario this would still be considered an
interesting binder. Also structural investigation of the binding mode would be
desirable. It is crucial to confirm the observed binding mode of the compound
is as predicted by DOCK 3.5.54 (Fig. 4.8 D). Nevertheless, this provides a first
success in ligand discovery for the SAM-I riboswitch.
Additionally the presented data only represent a first attempt in structure based
ligand discovery for the SAM-I riboswitch and the target is far from being thor-
oughly explored. Potential options include a virtual screening focused on the area
of the binding site usually occupied by the SAM methionine. Also docking into
the binding site configuration of the apo-structure is conceivable. A third op-
tion would be targeting the area of the binding pocket currently not occupied by
any ligand atoms next to the methionine moiety of the SAM ligand (Fig. 4.11).
Finally, it might be possible to utilize the identified compo9und as a building
block and synthesize compounds featuring this basic core with potentially higher
affinity.
The SAM-I riboswitch has been found in pathogens especially firmicutes includ-
ing the Bacillus genus for which effective novel treatment options are urgently
required. Compounds could be tested in the non-pathogenic model organism B.
subtilis which contains eleven SAM-I riboswitches in its genome before studies
with pathogenic organisms are carried out. The pathogenic species for potential
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Figure 4.11: Wall-eyed stereo view of a schematic representation of the SAM-
I riboswitch and its SAM binding pocket. The riboswitch is shown in cartoon
representation. The SAM ligand atoms are shown as spheres, red spheres for the
adenosine part of the ligand and amber spheres for the methionine part. The
cavity making up the binding pocket is shown as the transparent blue surface.
clinical application include B. anthracis, B. cereus and Listeria monocytogenes.
L. monocytogenes contains seven putative SAM-I riboswitches (Loh et al., 2009),
and is one of the most common food borne pathogens. The SAM-I riboswitch
would offer an opportunity of manipulating all genes regulated by these seven
SAM-I riboswitches simultaneously.
On a broader scope successful virtual screening studies for RNA targets are still
rare and the establishment of validated methods is vital towards development of
drug discovery methodology for RNA targets in general.
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Chapter 5
Stabilization of the k-turn in the
SAM-I riboswitch by tertiary
interactions
5.1 Results
5.1.1 Analysis of the SAM-I k-turn
The standard k-turn motif as identified from ribosomal structures (Klein et al.,
2001) can be described by the minimal consensus shown in Fig. 5.1 A. The T.
tengcongensis SAM-I riboswitch (see Fig. 5.1 B) contains a k-turn that matches
this consensus perfectly. The k-turn is found in the P2 helix (Fig. 5.1 C; Mon-
tange and Batey 2006; Montange et al. 2010). The k-turn introduces an angle
of about 60 ◦ in the P2 helix and places L2 in close proximity to J1/4 and
J3/4, allowing the formation of the central pseudoknot. The k-turn contains the
non-bulged strand residues comprising nucleotides 17-22 and the bulged strand
nucleotides comprising nucleotides 30-38. Even though the k-turn is essential for
folding of the riboswitch (Hennelly and Sanbonmatsu, 2010) and ligand binding,
no direct interactions are formed between the SAM-ligand and the k-turn region
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as can be seen in the structure of this riboswitch (Montange and Batey, 2006;
Montange et al., 2010). The SAM ligand in the crystal structure is located more
than 13 A˚ from the k-turn region (residues 17-22 and 30-38). In particular the
two G-A base pairs at the 1n-1b/2n-2b positions are more than 15 A˚ distant
from the SAM ligand. Consequently any influence of SAM binding on the k-turn
structure must be mediated through tertiary interactions of the RNA structure.
It appears that the k-turn provides a key element for the tertiary interactions
Figure 5.1: A: The consensus sequence of a standard k-turn. The individual
nucleotides are labeled according to the naming convention described in Liu and
Lilley 2007. B: The sequence of the SAM-I riboswitch k-turn C: Schematic draw-
ing of the overall structure of the T. tengcongensis SAM-I riboswitch. Shown are
the k-turn enabling the loop-loop interaction of P2 and the SAM-binding site.
The grey bars indicate areas of double helix but do not correspond to individual
base pairs.
that lead to the formation of the ligand binging site by positioning the L2 region.
Also the k-turn is formed in the apostructure in the absence of ligand (Stoddard
et al., 2010).
The near-consensus Kt-7 of Haloarcula marismortui is very similar in sequence
to the SAM-I riboswitch k-turn. The SAM-I riboswitch comprises three Watson-
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Crick base pairs at position of the -3 to -1 on the bulged and non-bulged strand.
The 1 to 3 nucleotides of both strands form consecutive GA base pairs, the
first two of which are extremely conserved in k-turns. The loop nucleotides con-
sist of the sequence G-A-U in the wildtype riboswitch (PDB-file 2gis; Montange
and Batey 2006) and G-A-C in the U34C/A94G mutant (PDB-file 3gx5). The
U34C/A94G mutant gave a higher resolution crystal structure (2.4 A˚; Montange
et al. 2010) and therefore this sequence was adopted for subsequent analysis.
Figure 5.2: A: Overall structure of the SAM-I riboswitch (PDB-code 3gx5) in
cartoon representation, the k-turn region in the black box, the SAM ligand (cyan
carbon atoms) in the red box. B: Superposition of the H. marismortui kt-7
(green cartoon representation) and the SAM-I riboswitch k-turn (blue cartoon
representation). The RMSD of the superposition of the two structures is 1.4 A˚.
Since the nucleobase of C34,which is located in the L3 position of the k-turn,
does not form any contacts within the riboswitch, this substitution is expected
not to alter the riboswitch binding properties. In solution the L3 base moiety is
pointing into bulk solvent and accordingly does not contribute any intramolecular
interactions. It is the optimized crystal contacts of the U34C substitution which
lead to better diffracting crystals by inter-molecular interactions, and thus this
variant forms a favorable system to study k-turn folding in the context of an
RNA molecule making important tertiary interactions.
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The three-dimensional structures of H. marismortui Kt-7 (PDB file 3cc2; Blaha
et al. 2008) and the SAM-I riboswitch k-turn superimpose with an RMSD of 1.4
A˚ (Fig. 5.2 B). A comparison of the structures shows the presence of all the
key hydrogen bonds of a standard k-turn (Liu and Lilley, 2007). The G1b-A1n
and A2b-G2n base pairs which have been shown to be of critical importance to
k-turn structure, are conserved. Both are trans sugar edge - Hoogsteen edge base
pairs and this interaction pattern is identical in Kt-7 and the SAM-I riboswitch
k-turn. Also the L1 O2’ interaction with A1n N1 which prevents k-turn folding
if disrupted is fully conserved between both k-turns. Since it is known that near-
consensus k-turns can fold in isolation (Matsumura et al., 2003; Goody et al.,
2004; Schroeder and Lilley, 2009), it was expected that the SAM-I riboswitch
k-turn would fold as an isolated duplex. The aim of the following experiments
was to probe the sequence requirements of a kink-turn in isolation and in the
context of a larger, structured RNA molecule to elucidate the possible role of
tertiary interactions in k-turn folding.
5.1.2 The SAM-I K-turn in isolation
The experiments presented in this section were carried out by Kersten T. Schroe-
der. Since they form an integral and essential part of the whole project they
are presented in the same detail as the other parts of the project. The SAM-I
riboswitch k-turn is known to fold in the context of the full aptamer domain from
structural data (Montange and Batey, 2006; Montange et al., 2010). However the
behavior of the k-turn in isolation was unexplored at the outset of the study. To
investigate this aspect, the SAM-I riboswitch k-turn sequence was incorporated
in a double helical RNA molecule which was 5’-terminally labeled with fluorescein
as a donor at one end and Cy-3 as an acceptor at the other (Fig. 5.3).
This construct allows the measurement of end to end distance and hence kinking
of the RNA-axis via FRET. The FRET efficiency was measured using the acceptor
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Figure 5.3: SAM-I riboswitch k-turn incorporated in a short RNA double helix
used for FRET experiments to measure k-turn folding. Each strand is 5’-labeled
with a fluorophore, either fluorescein or Cy3. Substitutions were made on the
1n-3n positions as described.
normalization method (Clegg et al., 1992). The value of EFRET in the absence
of metal ions is in good agreement with the expected value for a 3-base bulge
(Gohlke et al., 1994). As previously demonstrated for Kt-7, the end to end
distance decreases upon k-turn folding leading to an increased FRET efficiency.
Addition of magnesium ions to the SAM-I k-turn in isolation results in a change
of FRET efficiency ∆EFRET = 0.32, and the isotherm can be fitted to a simple
two-state binding model with a magnesium half concentration [Mg2+] 1
2
= 50 µM
and a Hill coefficient of n = 0.8 (Fig. 5.4).
The triple substitution A1nC/G2nU/G3nU was investigated in isolation, which
is expected to behave like a standard 3-base bulge without any k-turn folding
occurring upon magnesium addition as the three GA pairs are each converted to
Watson-Crick base pairs. Upon addition of magnesium ions no increase in FRET
could be observed (Fig. 5.5).
Next the extent of variation compatible with k-turn folding was explored. The
G2nU/G3nU variant underwent no folding in isolation (Fig. 5.5) similar to the
triple substitution. In contrast the G3nU variant (Fig. 5.4) exhibited partially
impaired folding, with ∆EFRET = 0.19, [Mg
2+] 1
2
= 110 µM and a Hill coefficient
of n = 0.9. As all modifications to the 1n and 2n bases were deleterious to k-turn
folding to this point, these positions were considered in more detail.
The An1C substitution gave no indication of folding (Fig. 5.4). Similarly the
A1nU substitution (Fig. 5.5) and the A1nG substitution exhibited no indication
of folding confirming that adenine is the only base in the 1n position that is
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Figure 5.4: EFRET of the k-turn constructs (Fig. 5.3) as a function of magnesium
concentration as measured by steady state fluorescence spectroscopy. Data were
fitted to a two state binding model. The natural sequence k-turn is represented
by filled circles, the G2nU substitution by open squares, the A1nC substitution
by open circles and the G2nA substituted k-turn by filled squares.
consistent with k-turn folding in isolation. Turning to the 2n position, all three
single substitutions of the G2n resulted in no observable folding.
In summary, all substitutions tested in the two GA base pairs adjacent to the loop
prevent k-turn folding in isolation while the G3nU mutation results in impaired,
but measurable folding ability.
5.1.3 Folding of the SAM-I riboswitch k-turn in context
of the riboswitch
The experiments presented here were conducted in collaboration with Kersten T.
Schroeder. Since the k-turn seemed very sensitive to modification in isolation,
it was investigated how this compares to the situation in context of the SAM-I
riboswitch. From the data available it was hypothesized that k-turn folding is a
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Figure 5.5: EFRET of the k-turn constructs (Fig. 5.3) as a function of magnesium
concentration as measured by steady state fluorescence spectroscopy. Data were
fitted to a two state binding model. The natural sequence k-turn is represented
by filled circles, the G2nC substitution by open squares, the A1nC/G2nU/G3nU
triple substitution by open circles, the A1nU substitution by filled triangles and
the G2nU/G3nU double substituted k-turn by filled squares.
key element in the global architecture of the riboswitch and therefore essential for
ligand binding. ITC measurements were performed with the standard k-turn and
the triple substitution G1nC,G2nU,G3nU to see if SAM binding might report
on k-turn foldability. For the standard k-turn sequence a binding constant of
KD = 0.5 ± 0.3 µM was measured (Tab. 5.1, Fig. 5.6 A), in agreement with
published data (Montange et al., 2010).
In contrast the triple mutant showed no heat evolution indicative of SAM binding
(Fig. 5.6 B). The ablation of the k-turn has evidently prevented the riboswitch
from adopting a conformation in which it can bind its SAM ligand. This suggests
SAM-binding can be used as a measure of k-turn foldability as hypothesized.
Next the riboswitch with a G3nU substituted version of the k-turn was probed
for SAM-binding and KD = 0.34±0.04µM was measured (Tab. 5.1 C). Heat was
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Figure 5.6: Isothermal titration calorimetry of SAM binding to the SAM-I ri-
boswitch with the natural k-turn and modified k-turns. SAM is titrated into a
solution of SAM-I riboswitch and the evolving heat is measured. Data are then
fitted to a two-state binding model and thermodynamic parameters are summa-
rized in Tab. 5.1.
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Table 5.1: Thermodynamic binding parameters determined by ITC for SAM
ligand titrated into a solution containing the SAM-I riboswitch. Data were fitted
to a two state binding model resulting in the tabulated parameters.
k-turn n ∆G◦ ( kJ
mol
) KD (µM)
natural 0.85± 0.10 −36± 1 0.5± 0.3
A1nC/G2nU/G3nU ND ND ND
G2nU/Gn3U 0.7± 0.1 −33.1± 0.4 2.0± 0.3
G3nU 0.74± 0.08 −37.6± 0.3 0.34± 0.04
A1nC ND ND ND
A1nU ND ND ND
G2nC ND ND ND
G2nA 1.04± 0.08 −37.8± 0.5 0.31± 0.06
evolved and the measured affinity was identical within error to that obtained for
the natural k-turn. A binding constant of KD = 2.0± 0.3µM was determined for
the G2nU/G3nU variant (Fig. 5.6 D, Tab. 5.1), which is about fourfold weaker
than the affinity of SAM to the riboswitch with the natural k-turn. A1nC (Fig.
5.6 E) and A1nU (Fig. 5.6 F) substitutions prevented measurable SAM binding
to the riboswitch. The same result was obtained for the G2nC substitution but,
surprisingly, the G2nA substitution exhibited SAM binding (Fig. 5.6 G) with a
binding constant of KD = 0.31± 0.06 µM which is comparable to the riboswitch
with the standard k-turn sequence (Tab. 5.1).
Despite preventing folding of the isolated k-turn, the A2n-A2b basepair does not
prevent SAM binding to the riboswitch, suggesting that the k-turn is folded nor-
mally. This indicates a stabilizing effect of the tertiary interactions within the
aptamer domain on the k-turn structure. However, SAM-binding is a very indi-
rect means of monitoring k-turn folding and the possibility that SAM binds by an
alternative conformation of the k-turn cannot be excluded. Therefore, structural
data were obtained to see if the k-turn region in these modified riboswitches is
folded into the conventional three-dimensional motif.
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5.1.4 Crystal structures of the SAM-I riboswitch with
G2nA and G2nU/G3nU substitutions in the k-turn
The riboswitch variant bearing the G2nA mutation in the k-turn region was
cocrystallised with SAM. Crystals were obtained in hanging drop format by mix-
ing 1 µL of mother liquor with 1µ L of 400 µM RNA plus 1 mM SAM in 40 mM
Na-cacodylate (pH 7.0). The mother liquor for the crystal used for data collection
contained 10 mM MgCl2, 40mM Na-cacodylate (pH 7.0), 12 mM spermine-HCl,
12 % (v/v) MPD and 80 mM KCl. The drops were seeded with a seed stock
containing crystals of the unmodified RNA. The crystallisation conditions de-
scribed above were very similar to those obtained in-house for the unmodified
riboswitch and the crystals had the same appearance. These conditions were
virtually identical with the published crystallisation conditions (Montange et al.,
2010). Crystals were cryoprotected in mother liquor containing 30 %(v/v) MPD
and mounted on cryo-loops followed by flash-freezing in liquid nitrogen.
Diffraction data were collected at the ESRF, with the best crystal diffracting to
2.6 A˚. A complete data set was obtained, and analysed to solve the riboswitch
structure bearing the G2nA mutation (Tab. 5.2).
The space group (P43212) and unit cell dimensions (a = b = 58.46 A˚, c=155.26
A˚, α = β = γ = 90 ◦) match those for the published structure of the unmod-
ified riboswitch (PDB-code 3gx5) closely. This allowed an initial model for the
modified riboswitch to be obtained by molecular replacement. This model was
subsequently refined with the R-factors for the final model being Rwork = 20.0 %
and Rfree = 25.9 %.
The overall fold of the G2nA structure is identical to that of the unmodified
riboswitch. An alignment based on the phosphorus atoms of all nucleotides of
the unmodified riboswitch and the G2nA variant yields an RMSD of 0.74 A˚.
Electron density is well defined for the whole riboswitch and the SAM ligand.
The k-turn region (nucleotides 17-22 and 30-38) of natural and modified ribo-
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Figure 5.7: Wall-eyed stereo image of the SAM riboswitch structure with a G2nA
substitution in the k-turn sequence. The structure is shown in grey cartoon
representation except for the SAM-ligand shown in green sticks and the k-turn
region and the loop-loop interaction which is shown in color.
switch align with an RMSD of 0.53 A˚(Fig. 5.8). The k-turns do not differ
significantly in their backbones. The 2Fo − Fc map shows that base and back-
bone regions are well defined by electron density for all residues (not shown). To
exclude the possibility of model bias, a composite omit map was calculated for
the final model using PHENIX (Adams et al., 2010). The backbone and most
nucleobases are also defined by the obtained composite omit electron density map
of the k-turn region (Fig. 5.9). It can therefore be concluded that the presented
model is not a result of model bias. Additionally the structure was validated with
MOLPROBITY (Chen et al., 2010) and performed comparably to the unmodified
riboswitch structure (Montange and Batey, 2006) The G2nA mutation creates an
A-A basepair at the 2n-2b position which differs in its hydrogen bonding pattern
from the G-A pair in the unsubstituted riboswitch. A single hydrogen bond from
A2nN3 to A2bN6 is formed. A2n also donates a hydrogen bond from N1 to O3’
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Figure 5.8: Wall-eyed stereo image of the k-turn from the unsubstituted SAM-
I riboswitch (grey) and the G2nA substituted variant (color). Both structures
exhibit the conventional k-turn fold, confirming that the G2nA substituted k-turn
fold is indeed salvaged by tertiary interactions.
of G1b. These two hydrogen bonds appear to lock the A2n into the observed
position, aided by base stacking of A2n between G18 and G35. This k-turn is the
first simple k-turn with such an A-A pair for which a structure has been deter-
mined. Interestingly the Thelohania solenopsae Kt-23 has an A2n-A2b basepair
in its natural sequence, although no structure is currently available.
In addition to the G2nA mutant, the crystal structure of the SAM-I riboswitch
with a k-turn sequence having a G2nU/G3nU double substitution was deter-
mined. This k-turn sequence was shown not to fold in isolation like the G2nA
substitution, but SAM binding to the riboswitch was observable, although im-
paired in context of the riboswitch (see above). Crystals were obtained using the
same method as for the G2nA substituted variant, and the drop containing the
crystal used for data collection contained 5 mM BaCl2, 40 mM Na-Cacodylate
(pH 7.0), 80bmM KCl, 12bmM spermine-HCl, 12 % MPD. Crystals were cryopro-
tected with mother liquor plus 15 % PEG. A crystal was mounted on a cryoloop
and diffracted to 2.9 A˚. Completeness was low in the highest resolution data
shell (64 % between 2.9 and 3 A˚), so the crystal structure is regarded as of 3 A˚
resolution.
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Figure 5.9: Wall-eyed stereo image of the k-turn region of the SAM-I riboswitch
with the G2nA substitution. The RNA is shown in cartoon representation and
the composite omit electron density map at 1 σ is shown in grey. The k-turn
model is well defined by the electron density.
The space group (P43212) was the same as for the unmodified riboswitch and
the unit cell dimensions are virtually identical. After molecular replacement
and refinement the final model (Rwork = 26.9 %/Rfree = 32.2 %) showed that
the overall fold of the riboswitch does not change compared to the unmodified
sequence. An RMSD of <0.5 A˚ is obtained upon alignment of the substituted and
original structure based on the phosphorus atoms of all nucleotides. In general
the riboswitch is well defined by electron density and the ligand is well defined
for the adenosine moiety but lacks observable density for the methionine moiety.
A composite omit map calculated for the final model confirmed the model free
of potential bias associated with the 2Fo − Fc-maps. The omit map at 1 σ-level
around the k-turn region is shown in figure 5.10; it defines the sugar-phosphate
backbone reasonably well but lacks density for many base moieties. Nevertheless
it can be concluded that the model represents the diffraction data well. Also
when the structure was validated using MOLPROBITY (Chen et al., 2010) it
performed comparable to the structure of the unmodified riboswitch Montange
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and Batey (2006)
Figure 5.10: Wall-eyed stereo image of the k-turn region of the SAM-I riboswitch
with the G2nU, G3nU substitution. The RNA is shown in cartoon representation
and the composite omit electron density map at 1 σ is shown in grey. While
the nucleobases are not well defined by the electron density, the backbone, in
particular the phosphate groups, defines the overall conformation of the k-turn
beyond doubt.
Looking at the k-turn region, an alignment (residues 17-22 and 30-38) based on
the phosphorus atoms, which are regarded to be the best defined backbone atoms
at this resolution yields an RMSD of 0.75 A˚. In conclusion the k-turn adopts
the conventional fold in context of the determined crystal structure despite the
impaired interactions of the 2n-2b/3n-3b base pairs.
5.2 Discussion
5.2.1 Folding of the k-turn in isolation
In this study, it was investigated how k-turns react to sequence alterations with
respect to their molecular environment. The folding of the k-turn motif in solu-
tion, one needs to be aware, involves a two-state dynamic equilibrium between
folded and unfolded states. The balance of this equilibrium is determined by
the relative energies associated with these states, which depends on parameters
including ionic strength, temperature and pH. In low ionic strength the repul-
sion between juxtaposed backbone atoms of the k-turn raises the energy of the
folded state above that of the unfolded state. Consequently, very few molecules
are found in the folded state which is therefore not observable by steady-state
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FRET. As the ionic strength rises, the repulsion between the backbone atoms
is shielded by diffuse counter ions and the energy of the folded state is lowered.
This raises the population of the folded state. In the FRET data this is reflected
in the smooth transition of low to high FRET efficiency. The natural sequence
SAM-I k-turn is a good example for this situation.
Alterations of the sequence of the k-turn changes the relative energies of the folded
and unfolded states. In some cases this results in a situation where the folded
states are never favored compared to the unfavored states resulting in a loss of
observable folding. An obvious example for this effect is the triple substitution
A1nC/G2nU/G3nU variant. The three Watson-Crick base pairs that result, lead
to a tight duplex with a three base bulge. The energy of the folded k-turn is
elevated to such a level that it will have virtually zero population.
In principle, any substitution can alter the energetic balance either by altering
the energy of the unfolded state or the folded state. As described for the triple
substitution A1nC/G2nU/G3nU a combination of both is possible. The further
substitutions described in the results section now probe to which extent the alter-
ation of the k-turn motif is compatible with folding by increase of ionic strength.
As described in detail in the results section almost all changes to the k-turn
sequence were deleterious for k-turn folding in isolation. This is due to the selec-
tion of substitutions which probed the critical nucleotides for k-turn formation.
The 1n and the 2n nucleotides do not tolerate any substitution without complete
obliteration of k-turn folding. This agrees with the data published for the H.
marismortui Kt-7 (Goody et al., 2004), and in context of the critical interactions
identified by substitution with modified nucleotides (Liu and Lilley, 2007; Turner
and Lilley, 2008).
The G3nU substituted k-turn exhibits a particularly interesting behavior. Fold-
ing is still observed with increase of ionic strength but the change in EFRET is
smaller and the FRET efficiency at high ionic strength is reduced compared to
the unmodified k-turn. This can be explained by the model for k-turn folding
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outlined above. At low ionic strength the unfolded state is energetically favored
and thus low EFRET is observed overall. As the ionic strength increases the ener-
getic balance shifts, and the now more favorable folded states dominate. However
the folded states are of slightly higher energy than for the unsubstituted k-turn,
so that even when the shielding effect is at full capacity a larger residual fraction
of unfolded states is present. It is important to observe that the [Mg] 1
2
of the
G3nU substituted k-turn is not different from the unsubstituted k-turn, which
indicates the substitution does not affect the shielding effect of the ions. The
different end points of the titration curves indicate an incomplete transition from
mostly unfolded to mostly folded states.
An alternative interpretation is the assumption that in the substituted k-turn
the folded states are geometrically different from the unsubstituted k-turn, for
example by an altered angle between the helical ends of the RNA. This would also
result in an increased average distance between the FRET partners and therefore
to a decrease in FRET efficiency. The identity of the transition point in the
substituted and unsubstituted k-turn however, supports the model of incomplete
transition.
5.2.2 k-turn folding in context of the SAM-I riboswitch
The situation which has to be considered for the interpretation of the ITC data is
quite different from the situation described above. First, under ITC assay condi-
tions the unmodified k-turn in isolation would be fully folded. Second, the readout
of k-turn folding is SAM binding which is primarily dependent on the ability of the
motif to fold in context of the riboswitch. Data indicating the importance of the
k-turn for ligand binding has been published (Hennelly and Sanbonmatsu, 2010).
As outlined earlier the SAM-I riboswitch has been crystallized in the presence
and absence of ligand (Montange and Batey, 2006; Montange et al., 2010; Stod-
dard et al., 2010). Therefore it can be concluded that the folded conformation is
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Figure 5.11: Schematic diagram of k-turn folding in isolation and in context of
the SAM-I riboswitch. In isolation the folded and unfolded k-turn are in an
dynamic two state equilibrium, with the relative occupancies for both states de-
termined by external parameters such as ionic strength. In case of the riboswitch
a three state equilibrium exists, the RNA in the ligand unbound form also is in a
dynamic equilibrium of states with folded and unfolded k-turns, but usually this
equilibrium is strongly dominated by the states with a folded k-turn. The states
with the folded k-turn are then able to bind SAM and SAM bound and unbound
states are in a second equilibrium. SAM binding locks the k-turn in its folded
state and stabilizes the molecule.
stable in solution in the absence of the ligand, at least for the isolated aptamer
domain. The situation in context of the aptamer domain and expression platform
might very well be different. The expression platform is expected to introduce
competition between alternative structures of the overall riboswitch but no data
are available for this case. Under the conditions of the ITC experiment, a certain
fraction of the aptamer domain will adopt conformations resembling that of the
crystallographically-determined apostructure which has the k-turn folded in the
absence of SAM ligand. This structure can bind SAM resulting in the evolution
of heat and a measurable binding curve. When the SAM-I aptamer is modified
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to disrupt k-turn folding, the SAM-binding conformation is inaccessible and no
binding is observed. The difference in behavior for k-turns in isolation and in
the context of the riboswitch stems from the additional contribution of tertiary
interactions to overall conformational energy. While for the isolated k-turn a
small change in the energy of the folded or unfolded states can tip the balance to
obliterate folding, in context of the riboswitch with its additional contributions
to folding the overall balance is expected to be more robust. In particular the
energy associated with the loop loop interaction of the P2 to the four nucleotides
in P4 may drive the k-turn towards the folded state.
The riboswitch bearing the unmodified k-turn of course folds and binds ligand,
and serves now as the standard for the behavior of riboswitches with modified
aptamers. The triple-substituted riboswitch does not exhibit any SAM binding,
indicative of disruption of k-turn folding. The SAM-binding conformation is not
accessible and thus disruption of the k-turn cannot be salvaged by the tertiary
interactions within the RNA molecule. Interestingly the same is true for the A1nC
and the A1nU-substituted variant. This supports the importance of the A1n-G1b
base pair for the stability of the k-turn fold, in agreement with previously reported
data (Goody et al., 2004; Turner and Lilley, 2008).
In case of the G2nA substitution the energetic balance is in favor of the folded
riboswitch since SAM binding deduced from the ITC is unchanged. Even though
the FRET experiments show that the folded state of the k-turn is not stable
in isolation, the tertiary interactions within the RNA can compensate and the
overall folding of the riboswitch is not measurably perturbed. The SAM ligand
can then bind to the aptamer domain similarly to the unmodified RNA. The
same analysis is true for G2nU/G3nU doubly substituted riboswitch. However,
a reduced affinity of the SAM ligand is observed. This can be explained by a
stabilization effect of the SAM ligand for the folded states. The energy of the
tertiary interactions is not sufficient to stabilize fully the folded conformation in
the absence of SAM. This could be demonstrated by footprinting experiments
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to determine the fraction of fully folded molecules. Therefore, part of the SAM
binding energy needs to compensate and stabilize the folded state, resulting in a
decreased net binding energy which is directly linked to SAM affinity.
5.2.3 Crystal structures of the SAM-I riboswitch with
modified k-turns
There is a possible alternative interpretation of SAM binding data for the G2nA
and the G2nU/G3nU variants invoking a SAM-binding conformation that might
exist without a folded k-turn. To test this possibility and to dissect further the
modified interactions in the substituted k-turns, crystal structures for both ri-
boswitch variants were obtained. The data for the G2nA-substituted variant
show that the conventional k-turn fold is conserved, preserving the A-minor in-
teractions and most of the standard hydrogen bonds. The computed composite
omit map demonstrates the validity of the crystallographic model beyond poten-
tial model bias. The G2nA substitution results in an overall loss of one hydrogen
bond but the nucleobase still maintains contacts to A2b as well as the 2’ hydroxyl
group of G1b. At the same time the A2n cannot form any favorable alternative
interactions with A2b. In conclusion the substitution probably leads to a slight
elevation of the energy of the folded state while the energy of the unfolded state
is not markedly altered. The loss of energy associated with this hydrogen bond
can then be compensated for by the overall folding energy of the riboswitch.
For the G2nU/G3nU substituted riboswitch the data are not of comparable qual-
ity. A resolution of 2.9 A˚ in combination with low completeness in the highest
resolution shell led to electron density maps that reveal much less detail. Never-
theless, the overall fold of the riboswitch and the k-turn could be confirmed. The
composite omit map allowed tracing of the backbone at least while the orienta-
tions of individual nucleobases remained elusive. In conclusion the data certainly
confirm the conventional k-turn fold for the G2nU/G3nU substituted riboswitch,
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but a more detailed analysis of the contributions of individual intramolecular
interactions to the behavior of this variant is not justified by the available data.
5.2.4 Conclusions
The data presented suggest a delicate energetic balance of folded and unfolded
states for the natural SAM-I k-turn in isolation. This balance is easily perturbed
by substitutions in the key bases defining the k-turn motif with major effects on
folding. However, in the context of a larger RNA-molecule such as the SAM-I
riboswitch, folding is in some cases maintained by the contribution of intramolec-
ular tertiary interactions. This demonstrates that, in addition to protein binding
and high ion concentration, tertiary interactions provide a third mechanism for
the stabilization of the conventional k-turn fold.
However, several open questions remain and further experiments are needed to
understand fully the folding of the k-turn motif. Single molecule studies have
contributed considerably to the understanding of RNA folding in several cases
(Lemay et al., 2006; Ouellet et al., 2010; Neupane et al., 2011). Recently, a study
has applied single molecule measurements to the SAM-I riboswitch (Heppell et al.,
2011), but this study did not look at the k-turn folding in any detail. Therefore,
applying single molecule studies to the SAM-I riboswitch k-turn both in isolation
and in context of the riboswitch would elucidate the k-turn folding further.
Furthermore, it remains unknown whether in principle any real k-turn sequence is
compatible with riboswitch folding. Or phrased differently, can the SAM-I k-turn
be replaced by k-turn sequences from the ribosome of different species. This leads
to the question whether different k-turns are slightly different in terms of their
kink-angle or in terms of the introduced helix torsion. Most of the ribosomal
crystal structures from which k-turn structures were derived have a resolution
> 2.5 A˚ and are structures of very large complexes (Schluenzen et al., 2000;
Klein et al., 2001; Weixlbaumer et al., 2008). Consequently individual k-turns
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might not be optimally modeled, or small differences in structure might have been
missed. It is conceivable that there are classes of distinct k-turn geometry. If this
were the case k-turns of the same class would be expected to be interchangeable
in a riboswitch context, while k-turns of a different class from that found in the
original riboswitch might prevent folding.
Chemically synthetic RNA for the full length riboswitch is currently becoming
available from commercial suppliers. This will enable dissection of the contribu-
tion of individual hydrogen bonds to k-turn folding in context of the full aptamer
domain, similar to what has previously been done with H. marismortui Kt-7 in
isolation (Liu and Lilley, 2007).
Finally, the identification of tertiary interactions as a folding factor for k-turns
might be important for the assembly of the ribosome itself, since many ribosomal
k-turns found in biological context deviate from the consensus sequence. In case
of the T. solenopsae Kt-23 from the 16S rRNA, the A2n-A2b basepair occurs
naturally. The correct k-turn fold can in this situation be driven either by the
binding of the ribosomal proteins or by the tertiary interactions within the rRNA.
This has implications on the possible mechanisms of ribosome biogenesis. Either
the tertiary interactions drive the k-turn folding which then allows protein binding
or vice versa. Since k-turns are found multiple times in the ribosome structure
it can be assumed that they are an important structural feature of ribosomes. A
better understanding of the k-turn motif and the parameters vital to its folding
will to contribute to a better understanding of the ribosome and its biogenesis.
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Table 5.2: Statistics on data collection and refinement for the SAM-I riboswitch
structures with modified k-turn sequences.
Sequence G2nA G2nU/G3nU
PDB code 2ygh 2ydh
Space group P43212 P43212
Unit cell dimensions (A˚) a=b=58.64 a=b=61.89
c=155.26 c=157.63
α = β = γ = 90◦ α = β = γ = 90◦
Resolution range (A˚)1 51.8-2.6 (2.74-2.6) 50-2.9 (2.0-2.9)
Observations 82286 41985
Unique observations 8929 6875
Completeness (%) 100.0 (100.0) 93.1 (64.5)〈
I
σ(I)
〉
22.6 (6.0) 40.6 (2.4)
Rmerge(%)
2 7.0 (38.3) 5.1 (42.3)
Multiplicity 9.2 (9.5) 6.1 (5.6)
Refinement statistics
Resolution range (A˚) 51.8-2.6 50-2.9
Rwork/Rfree(%)
3 20.0/25.9 26.9/32.2
Number of atoms RNA/ligand 2033/27 2024/27
Number of atoms ions/water 6/19 5/2
Mean B-factor RNA/ligand 28.8/21.3 96.9/77.3
Mean B-factor ions/water 25.0/17.0 161.7/30
RMS bond length deviation (A˚) 0.01 0.01
RMS bond angle deviation (◦) 1.892 1.914
1Values in brackets are for the highest resolution shell.
2Rmerge =
∑
(|I − 〈I〉| /I)
3R-factor=
∑ |Fo − Fc| /∑Fo
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Chapter 6
Concluding remarks and future
perspective
6.1 Conclusion
All results presented and discussed above focus around the central question of
structure and ligand recognition in riboswitches. While the different chapters
focus on different aspects of this central topic one central theme seems to be
common to all three of them: Individual interactions on a molecular level are
generally understood and can be explained from theory, however their interplay in
a given molecular scenario and the resulting consequences are far less understood.
6.1.1 Examples from the GRA
In the case of the purine riboswitch the importance of a water molecule for
ligand binding was revealed. While binding of water molecules to biological
macromolecules and the concept of water-mediated receptor ligand interactions
are not difficult in themselves, treatment of these effects in a docking scenario is
still a challenge in the field (Schneider, 2010). The fine balance between energetic
cost and benefit of water binding and the identification of potential locations for
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such water molecules are the subject of intense investigations.
The correct treatment of protonation and deprotonation of functional groups
from both ligand and receptor is a second example for lack of understanding
of the interplay between different effects. While the concept of pKa values is
one of the most basic principles in chemistry the prediction of these pKa values
and their variability in different environments for a given molecule is still chal-
lenging (Klebe, 2006). Recently more sophisticated models have been proposed
and applied (Liao and Nicklaus, 2009; Kalliokoski et al., 2009; Manchester et al.,
2010).
6.1.2 Examples from the SAM-I riboswitch
A problem similar to pKa prediction was aqueous solubility of the compounds
selected from the virtual screening of the SAM-I riboswitch. Even though the
principle factors influencing solubility are known, prediction of solubility for a
given compound in a given solvent is still not an easy task. Even though pre-
dictors are available, they are far from reliable and aqueous solubility is usually
approximated by the partition coefficient between n-octanol and water when sol-
ubility is assessed for a large number of compounds.
While the effects on the results of the ligand screening for the SAM-I riboswitch
cannot be quantified, binding site flexibility was shown to be an important feature
of the SAM-I riboswitch (Stoddard et al., 2010). Induced fit binding mechanisms
and rearrangement of residues in the binding site are a well known challenge
in docking (Yuriev et al., 2011; B-Rao et al., 2009). Efforts to include receptor
flexibility into docking algorithms have a long history but success has been limited
and research in this field is ongoing. A comprehensive understanding of RNA
folding to a degree that would allowed incorporation of RNA flexibility into the
prediction methods for ligand binding is still elusive.
In summary, for all cases mentioned above the individual contributions are under-
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stood and can be rationalized but their interplay in a complex molecular scenario
cannot be predicted. Seen from a different angle experimental results are rational-
ized readily using fundamental principles but prediction of experimental results
from these very principles is challenging. However, the success of molecular dock-
ing demonstrated above shows that at least for some scenarios a qualitative and to
some degree even quantitative understanding of ligand binding can be achieved.
The utilized scoring function with its terms for electrostatic, van der Waals and
desolvation energy was successful in approximating the energetics of binding and
predicting the experimentally observed behavior. Interestingly, all the problems
encountered in RNA-ligand docking are well known from protein-ligand docking
and no RNA specific issues were identified in the chosen systems.
The results for the SAM-I k-turn in isolation and in the context of the riboswitch
show that obtained data can be interpreted at a high level of detail. The k-turn
offers the opportunity to study folding of a structural motif at the level of indi-
vidual molecular interactions in a variety of environments. Quantification of the
contribution of individual hydrogen bonds in different molecular environments
seems feasible. The experiments performed demonstrate the power of combining
quantitative folding assays with X-ray crystallography to understand the struc-
ture determining factors of the k-tun motif.
6.2 Long term perspective
The main challenge for molecular modeling and the detailed investigation of mo-
lecular systems in general will be to accurately include the interplay of different
molecular effects and balance their individual contributions in order to predict
the behavior of the system under a given set of parameters. In the past attempts
to do so have been only of limited success and one problem observed was that
with every additional effect considered new problematic situations appear. This
was described as an ”endless staircase” (Schneider, 2010) for molecular docking.
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One way forward seems to perform detailed analyses of a single effect in a well de-
fined model system to dissect the different contributions in a known setting. From
there gradual generalization can be attempted. It remains to be seen whether
this approach is feasible for all cases and weather some of the challenges will
just prove to be too hard to tackle. The other avenue of progress apparent is to
use the rapidly evolving computational technology and use more computational
resources for the problem at hand. Originally, docking algorithms used very sim-
plified models of ligand binding. The consideration of flexibility was simply not
within reach of the computational resources. Recently, techniques and algorithms
much more computationally demanding, such as molecular dynamics simulations,
have been integrated into docking protocols (Marco and Gago, 2007). Again time
will have to show whether simply increasing the computational resources will lead
to a better overall performance of the predictors.
6.3 Short term goals and next steps
Finally the question remains, where to continue with the research presented
above. For the docking part of the results, it can be said that both riboswitches
used have not been exhausted as model systems for RNA-ligand docking. The
purine riboswitch has so far only been looked at for the U74 version and whether
the C74 version will yield comparable results is yet to be determined. Prelimi-
nary data on the C74 variant suggests that the docking approach will perform
similarly. The purine riboswitch with its relatively small binding site would also
be suitable for a more detailed retrospective study testing and validating im-
provements in the treatment of pKa effects and tautomerization. Docking into
the receptor conformation observed in the 2’-deoxyguanosine bound structure
(Edwards and Batey, 2009) is an attractive option as well. The enlarged binding
site would allow exploration of a larger chemical space in the context of a known
system.
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For the SAM-I riboswitch further docking could be performed varying several
parameters, including docking into the apostructure, and focusing on the area of
the binding pocket usually binding the methionine moiety of the SAM ligand.
The optimization of the docking protocol to include the full conformational space
for the ligand could use the SFG and SAH bound structures of this riboswitch
as a starting point.
For the aspect of k-turn folding three main avenues of interest can be identified:
1. Investigation whether the k-turn in the SAM-I riboswitch can be replaced
by other k-turns, such as the ones found in the ribosome.
2. After identification of three main contributors of k-turn folding (intrinsic
foldability, protein binding and tertiary interactions) it would be interesting
to see how the different factors are of different importance for different k-
turns in their native environment.
3. Use of synthetic full length SAM-I riboswitch including modifications at
key residues to dissect the key interactions of the k-turn in the context of
the full riboswitch.
In summary the systems chosen for experimental and computational investigation
have helped to further the understanding of molecular recognition and folding in
riboswitches as well as RNA in general. For most of the problems encountered
starting points for optimization and many experiments to be performed in the
future could be identified.
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Appendix A
List of Abbreviations
• A adenine
• AR V. vulnificus adenine riboswitch
• AUC area under curve
• C cytidine
• DMSO Dimethyl sulfoxide
• DNA deoxyribonucleic acid
• DTT dithiothreitol
• EDTA ethylenediamine tetraacetic acid
• ESRF European synchrotron radiation facility
• FMN flavin mononucleotide
• FRET fluorescence resonance energy transfer
• GMP guanosinemonophosphate
• GRA xpt-pbuX guanine riboswitch C74U mutant from Bacillus subtilis
• G guanine
• HCV hepatitis C virus
• HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
• HIV human immunodeficiency virus
128
• HPLC high performance liquid chromatography
• ITC isothermal titration calorimetry
• MPD 2-methyl-2,4-pentanediol
• mRNA messenger RNA
• NTP nucleoside triphosphate
• PCR Polymerase chain reaction
• PDB protein databank
• PEG polyethylene glycol
• RMS root mean square
• RMSD root mean square deviation
• RNA ribonucleic acid
• ROC receiver operating characteristic
• rRNA ribosomal RNA
• SAC S-adenosylcystein
• SAH S-adenosylhomocystein
• SAM S-adenosylmethionine
• SFG sinefungin
• snoRNA small nucleolar RNA
• snRNA small nuclear RNA
• T thymine
• TAR transactivation response element
• t-BDMS tert-butyldimethylsilyl
• TPP thiamine pyrophosphate
• Tris 2-amino-hydroxymethyl-propane-1,3-diol
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• tRNA transfer RNA
• U uracil
• UV ultra violet
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